

Cite this: *Food Funct.*, 2020, **11**, 9397

Simulating human digestion: developing our knowledge to create healthier and more sustainable foods

Alan Mackie, *^a Ana-Isabel Mulet-Cabero^b and Amelia Torcello-Gómez ^a

The gold standard for nutrition studies is clinical trials but they are expensive and variable, and do not always provide the mechanistic information required, hence the increased use of *in vitro* and increasingly *in silico* simulations of digestion. In this review, we give examples of the main simulations being used to model upper gastrointestinal tract digestion. This review ranges from the selection of enzymes to the interpretation of results from static models to fully dynamic models. We describe the modifications made to accommodate different demographic groups (infants, the elderly, etc.). We list examples of the application of the different models as well as giving the advantages and disadvantages. A model is only useful if it predicts or aids the understanding of physiological behaviour. Thus, the final section of the review makes a comparison of results obtained from experiments undertaken using *in vitro* simulations with those obtained *in vivo*. This comparison will help the reader understand the appropriateness of each model for the type of measurement to be undertaken. In particular, human studies tend to measure bioactive concentrations in blood and not in the gastrointestinal tract whereas *in vitro* studies often only produce data on release of nutrients into the gut lumen. This is the difficulty of comparing bioaccessibility as generated *in vitro* with bioavailability as generated *in vivo*. It is apparent that the models being used are increasingly being validated with *in vivo* data and this bodes well for the future.

Received 28th July 2020,
Accepted 21st October 2020

DOI: 10.1039/d0fo01981j

rsc.li/food-function

1. Introduction: why use *in vitro* rather than *in vivo*?

1.1 The rationale

There has been an increasing emphasis on the link between food and health. As a result, there is a desire for better understanding of the mechanisms involved and this has led to the use of a wide range of models to simulate human digestion.¹ These include a variety of *in vitro* simulations of the gastrointestinal (GI) tract capable of predicting bioaccessibility (*i.e.* fraction of a compound that is released from the matrix and is available for absorption).² In reality, it is generally difficult to validate such models because bioaccessibility is hard to measure *in vivo* in humans.³ The ability to predict the bioaccessibility of specific compounds is important if we are to optimise the health benefits of particular foods in the diet. This optimisation is only possible if the various factors controlling the bioavailability of bioactives are well understood. Bioavailability, *i.e.* the proportion of a bioactive reaching the site of action, is a balance

between rates of clearance or metabolism and rates of absorption and transport. Thus, increasing bioaccessibility is a key step in increasing bioactivity and the predictive power of even simple models becomes important.⁴ It is essential to understand that bioaccessibility is a prerequisite step for bioavailability⁵ and *in vitro* experiments that are representative of physiological conditions can provide useful indications of likely bioavailability in a wide range of food systems that would not be practical to test in human feeding studies. In this review, we discuss the key issues associated with undertaking physiologically relevant simulations of human digestion and how results compare to data from human studies.

1.2 Summary of the digestion process

Digestion consists of a number of distinct processes that convert the food we eat into absorbable nutrients that sustain our bodies. The intake of food and the subsequent flow of digesta from one compartment to the next is tightly controlled by a number of different sensing and feedback mechanisms that have evolved to optimally extract the nutrients from food.⁶

The physical process of digestion starts in the mouth where food is chewed and mixed with saliva.⁷ Solid and semi-solid foods are broken down into small particles and combined with saliva into a bolus. The properties of the bolus can have a significant influence on subsequent digestion.⁸ The bolus is held

^aThe School of Food Science and Nutrition, University of Leeds, Leeds, LS2 9JT, UK.
E-mail: a.r.mackie@leeds.ac.uk

^bQuadram Institute Bioscience, Norwich Research Park, Norwich, Norfolk NR4 7UQ, UK



together and lubricated by saliva. The saliva also contains amylase that starts the hydrolysis of starch. Although oral processing serves many other functions associated with the sensory perception of food, these are not directly related to digestion. From the mouth, food passes down the oesophagus to the stomach.

The stomach is essentially a storage vessel that controls the release of nutrients into the small intestine, which is the main site of hydrolysis and absorption. The environment in the stomach varies both spatially and temporally. Immediately after a meal has entered the stomach, the pH will be relatively high (just slightly lower than the food itself, depending on buffering capacity) and the enzyme concentration relatively low. However, this soon changes as HCl is secreted and the pH drops, and both pepsinogen, the zymogen of pepsin, and gastric lipase are also secreted. The different enzymes present in the chyme, including salivary amylase, are active over different pH ranges and thus the hydrolysis of macronutrients occurs sequentially. The salivary amylase present in the bolus will be active until the pH drops below about 3.8.⁹ Next, the gastric lipase will become active as it has an optimum of pH 5–5.4¹⁰ and then finally the pepsin will start to hydrolyse any protein present as the pH drops to its optimum of ~pH 2.¹¹ In reality, there is significant overlap in the conditions under which these different enzymes can function as they all have some activity outside their optimum pH. After the physical processing of the oral stage, the gastric phase is relatively inactive in relation to physical processing. Only in the antrum and through the pylorus there is significant shearing of the gastric content. In other parts of the stomach there is relatively little mixing and stirring. Thus, phase separation can occur as lipids rise to the top and liquids are emptied in preference to solids. During emptying, particles larger than ~2 mm will tend to be retained while smaller particles are emptied. The rate at which chyme passes from the stomach to the duodenum is a function of the caloric density of the chyme and its rheological properties¹² with nutrient dense and more solid chyme being emptied more slowly than nutrient poor liquids.

From the stomach, chyme passes into the small intestine that comprises the duodenum, where gastric contents mix with bile and pancreatic enzymes and the pH is neutralised, the jejunum and the ileum. The pancreatic enzymes secreted into the duodenum include a range of lipases and proteases as well as amylase and other enzymes. The contents of the small intestine are well mixed and the relatively high enzyme activity quickly leads to the production of hydrolysis products. These products diffuse through the protective mucus layer to the underlying epithelium for further hydrolysis by brush border enzymes and absorption. Absorption by enterocytes is usually transporter mediated rather than “passively” absorbed. Bile, secreted into the duodenum from the gall bladder is largely reabsorbed in the distal ileum with *circa* 5% passing into the colon.

Any digesta that has not been hydrolysed and absorbed in the small intestine passes into the colon through the ileocecal valve. The high microbial load in the colon drives the fermenta-

tion of dietary fibre, especially soluble fibre, and the metabolism of a wide range of bioactive compounds such as phenolics.

1.3 Advantages of *in vitro* digestion

The use of *in vitro* simulations of human digestion has become widespread because they are less labour intensive, less expensive, more rapid and do not have the ethical restriction that *in vivo* studies have. They are suitable for mechanistic studies and hypothesis building due to their controlled conditions, reproducibility and ease of sampling at the site of interest.¹³ However, as mentioned in the introduction, such models are only useful if they are predictive of functionality *in vivo* and can provide some mechanistic insight. The Infogest network was set up in order to provide some guidance in using simple but physiologically relevant simulations of upper GI tract digestion.¹⁴ In order to be able to compare studies there is also a need for some standardisation. Indeed, one of the advantages of such simulations is that they avoid inter-individual variations that are often seen in human studies. Despite the widespread recognition that both physiological relevance and standard protocols are important, we still see significant numbers of publications using specific protocols with a modification that means it is no longer standardised.

In addition to the advantages listed above, models can be chosen to address specific questions. For example, static models of digestion can be used to determine end-points of digestion or kinetics of very specific steps of digestion such as small intestinal hydrolysis. Thus, food digestibility can be assessed relatively simply and more complex models can be chosen if the question is more about the rate of appearance of specific nutrients or bioactives in the blood stream.¹⁵

1.4 Disadvantages of *in vitro* digestion

As indicated in the Introduction, the health implications of dietary interventions are related to local concentrations of the bioactive under investigation at the site of action. It is often not clear how this relates to bioaccessibility and further it is not easy to validate bioaccessibility as it normally involves either animal experiments or intubation of study participants.¹⁶ In the case of validation in animals, there is always the question as to whether the same outcome would be seen in humans. These limitations to validation mean that the reliability of *in vitro* digestion is questionable. Another potential disadvantage is their ease of use. This initially looks like an advantage but can mean that digestion models are used inappropriately, for example to digest ingredients in isolation.

2. Models and ingredients (horses for courses). Tailoring the model to the question

2.1 Ingredients

The activity and specificity of enzymes vary depending on their source and concentration and thus specifying activity is critical



when simulating human GI digestion. Of course, the enzymes should be dispersed in physiologically relevant media with appropriate pH and ionic strength, as will be described in later sections for the different models of *in vitro* digestion. In addition, the presence of biological surfactants will ultimately influence the performance of enzymes on the different substrates, such as lipids or proteins.^{17–19} Finally, suitable food substrates must be taken into consideration since the effect of the food matrix also plays an important role in the hydrolysis of food components.⁴ Having this in mind, each of these components is briefly reviewed in this section for suitable use within the context of biological relevance and standardisation of static or semi-dynamic *in vitro* digestion models to enable comparisons across different research laboratories.^{13,20,21}

Regarding the source of the digestive reagents, when human source is not commercially available, enzymes of porcine and bovine origin are usually recommended because of the biological similarity to those of human species. Starting in the oral cavity, the use of human salivary α -amylase is recommended over porcine pancreatic α -amylase¹³ but this is only relevant if starch is present in the food substrate. Furthermore, amylase will play a more significant role in a semi-dynamic model of digestion, as will be further explained below, since the initial pH in the simulated stomach is more elevated and amylase could still be active. Continuing in the stomach, the use of gastric lipase is now accessible. A rabbit gastric extract is commercially available from Lipolytech®.¹³ This extract also contains pepsin, which must be accounted for in the total pepsin activity.²² Rabbit gastric lipase shares 85% of sequence homology with human gastric lipase²³ and has been shown to mimic well the digestive properties of human gastric lipase²⁴ due to similar regio- and stereo-preference and pH-sensitivity.¹⁰ Additional porcine pepsin might be needed to meet the required activity in the simulated stomach. The use of phospholipids in the gastric phase is only recommended if proteolysis is the focus of the study and they are not present in the food substrate. This is because phospholipids have shown to affect the rate of protein digestion in the gastric and intestinal phase,^{18,25} but this step is optional. The detailed protocol to prepare phospholipids vesicles can be found elsewhere.²⁰ In the intestinal phase, pancreatin from porcine pancreas is used as a cocktail of pancreatic enzymes (proteases, lipases and carbohydrases) and the amount is intended for general purposes in the digestion of food and is based on trypsin activity. For substrates where the focus of study is lipid hydrolysis, the addition of porcine pancreatic lipase is also recommended to meet the required lipase activity. In cases where only starch, protein or lipid comprises the substrate, then individual porcine pancreatic amylase, proteases trypsin and chymotrypsin (from porcine and bovine origin, respectively) or porcine pancreatic lipase and colipase, respectively, can be used. The use of individual enzymes in this specific situation is also an advantage in reducing the interference of additional components in the analysis of the digesta. Digestion in the small intestine occurs in the presence of biosurfactants such as bile salts and phospholipids. For a

more physiologically relevant scenario, and when testing complex food matrices comprising proteins and lipids, the use of commercial bile extracts is suggested. These bile extracts contain a biological mixture of bile acids, phospholipids and cholesterol.²⁶ In particular, the bile composition from bovine bile extract has been reported to be closer to human bile composition than porcine source.²⁴ The activity of the enzymes and the content of bile in the extracts should be carefully measured and the appropriate assays are provided in the supplementary material of Brodkorb *et al.*¹³

The use of GI juices from human aspirates for *in vitro* digestion of proteins and lipids has been reported previously.^{27–29} Despite the closer approach to the *in vivo* secretions, it may represent more limitations than advantages for the following reasons. The restricted accessibility, the low storage stability of the aspirates in terms of enzyme activity and its complex characterisation, and inter-individual variability³⁰ may lead to poor reproducibility and difficult comparison across studies. The inter-individual variability can be reduced if batches of pooled gastric and intestinal juices from a large cohort are used. Asledottir *et al.* used the standard protocol of static *in vitro* digestion²⁰ by replacing the simulated GI fluids with pooled human gastric and intestinal aspirates and measured the enzyme activities with the recommended assays mentioned above.²⁹

2.2 Static *in vitro* digestion models

The simplest *in vitro* digestion models are static, which are relatively easy and cheap to use on a daily basis. These models may consist of a mono-compartmental test, simulating for instance only the gastric phase, or a multi-compartment test where oral, gastric and small intestinal phases are simulated in sequence. The parameters of static models are fixed. This means that the meal to secretions ratio, pH, and enzyme/biosurfactant concentrations are set from the beginning of each phase and are constant throughout the respective phase. These fixed values should represent a physiologically relevant average of the GI scenario. For example, a simulation of the gastric phase in the fed state is proposed to be at the gastric emptying half-time.²⁰ Nevertheless, these representative values vary according to human conditions of age, fed/fasted state and healthiness, among others. In addition, the stirring/shaking conditions with constant speed throughout each phase enable homogeneous mixing, which may allow a more representative sampling, but is certainly not characteristic of the very mild mixing found in certain sites, like the fundus in the stomach. Static models oversimplify digestive physiology, failing to mimic the dynamic aspects of the digestive process especially the mechanical forces and fluid dynamics, as well as pH gradients, continuous secretions or gastric emptying, in a series of rigid vessels under continuous stirring. Thus, the static models are mainly used for mechanistic studies and hypothesis building with specific applications for screening purposes.³¹

Various static models used in the past have been developed for very specific purposes. A mono-compartmental protocol



has been used for evaluating protein digestion in the context of protein allergenicity, called pepsin resistance test.^{32,33} This protocol represents the gastric conditions close to the end of gastric emptying or fasted state, which are highly acidic and include a high concentration of pepsin (Table 1). This test has been recommended by the European Food Safety Authority for screening purposes and the comparison with other physiologically relevant scenarios has been encouraged,³⁴ such as simulation of gastric fed state conditions and addition of a subsequent intestinal phase. In this context, a standardised static protocol of *in vitro* digestion suitable for food was successfully developed by the Infogest network,²⁰ which was based on *in vivo* data and validated with a ring trial.¹⁴ This model is standardised for comparison across laboratories since enzymatic parameters are expressed in standard units of enzyme activity, and experimental assays are explicitly included for accurate enzyme activity and bile acids characterisation. The protocol comprises a multi-compartment model simulating an oral, gastric and small intestinal phase in sequence with GI conditions representative of a healthy fed state human adult. The average gastric pH is higher than in the fasted state and the average pepsin concentration is lower (Table 1). A recent publication has dealt with some new updates to this protocol,¹³ such as the inclusion of an oral phase regardless of the nature of the food matrix, and more detail about the use of gastric lipase.

There is also a need for standardising static models targeting different age populations, such as infant and elderly. The immature gut in healthy infants and the deteriorated GI functions in the elderly represent different conditions to those in healthy adults, which may lead to different outcomes of nutrient bioaccessibility.

2.2.1 Infant digestion protocols. Before considering infant gut conditions, the first assumption associated with this age (zero to six months) is that liquid milk-based formulations

comprise the only kind of meal. This limits the duration of the oral phase to the swallowing time, and along with the low levels of salivary α -amylase^{38,39} justify the omission of an oral phase preceding the gastric phase. Infant saliva has on average only ~10% of the α -amylase activity in adults,⁴⁰ but its ingestion compensates for the absence of pancreatic α -amylase in infants.⁴¹ The average gastric pH (~5) is more elevated than in adults,³⁸ in part because of the frequent feeding (every three hours) and because of the lower proton pump activity.⁴² This higher gastric pH is within the optimum range of gastric lipase (pH 3–5)¹⁰ but decreases the optimum pepsin activity found at the pH range of 1.6–4.⁴³ The gastric emptying half-time is shorter, with an average time of approximately 60 min measured for breast milk and infant formula.⁴⁴ In addition, the concentration of some GI enzymes and bile acids is lower as reviewed recently.^{38,40,42,44} However, gastric lipase levels in infants have been shown to be similar to those in adults.⁴⁵ The enzyme remains active over a wide range of gastric pH (1.5–7) and retains some of its activity throughout the GI tract,¹⁰ compensating the reduced amount of pancreatic lipase in infants, 5–10% of the activity in adults.⁴⁶ Gastric lipase plays a crucial role in triglyceride digestion within breast milk since it is able to access the native milk fat globule membrane without the need of bile acids or other co-factors, facilitating the subsequent lipolysis by duodenal lipases.⁴⁷ Since the commercialisation of rabbit gastric extract is very recent (2014–2015),⁴⁷ most of the early *in vitro* infant models may have omitted the use of gastric lipase or used alternative sources.

GI conditions of the infant population have generally been neglected for *in vitro* studies until the last decade. The static infant models reviewed here are only those with physiologically relevant gastric pH and reasonable levels of gastric and intestinal enzymes and bile acids. One of the first studies using static infant (younger than 6 months) *in vitro* digestion used a

Table 1 Average parameters summarising the GI conditions in static *in vitro* digestion models. SSF: simulated salivary fluid; SGF: simulated gastric fluid; SIF: simulated intestinal fluid. In the intestinal phase, the amount of pancreatin extract is based on trypsin activity

		Infant ^a	Adult (fed state) ^b	Adult (fasted state) ^c	Elderly ^d
Oral	pH	—	7	—	6.8
	Meal : SSF (w/v)	—	50 : 50	—	50 : 50
	α -Amylase (U mL ⁻¹)	—	75	—	150
	Time (min)	—	2	—	3 s
Gastric	pH	5.3	3	1.2	4
	Oral bolus : SGF (v/v)	63 : 37	50 : 50	5 : 95	40 : 60 initial
	Pepsin (U mL ⁻¹)	268	2000	2500 (10 000 U mg ⁻¹ test protein)	450 initial
	Gastric lipase (U mL ⁻¹)	19	60	—	153 initial
	Time (min)	60	120	60	180
Intestinal	pH	6.6	7	—	6.5
	Gastric chyme : SIF (v/v)	62 : 38	50 : 50	—	—
	Trypsin (U mL ⁻¹)	16	100	—	46
	Pancreatic lipase (U mL ⁻¹)	90	2000	—	—
	Bile acids (mM)	3.1	10	—	5.34
	Time (min)	60	120	—	180
Suitability		Liquid food	Liquid/solid food	Protein solutions	Liquid food

^a Data from Menard *et al.* (2018).³⁵ ^b Data from Minekus *et al.* (2014) and Brodkorb *et al.* (2019).^{13,20} ^c Data from Thomas *et al.* (2004).³³ ^d Data from Levi *et al.* (2014) and (2017).^{36,37} The gastric pH corresponds to that at the emptying half-time.



gastric and an intestinal phase in sequence with relevant stomach pH (4), low pepsin and pancreatin activities and bile acid concentration, followed by continuous-flow dialysis.⁴⁸ Their results showed a good agreement on the bioaccessibility of minerals from human milk, cow's milk-based and soy-based formulas with previous data in term healthy infants. Another study on *in vitro* digestion of human milk used human neonatal gastric juice adjusted to different pH values (6.5–2) to simulate the stomach conditions in infants.⁴⁹ The authors found that milk proteins were only digested at relatively low pH values (<4), which are not representative of physiological conditions in infants. Nevertheless, *in vitro* results at pH 4–6.5 were in good agreement with the *in vivo* results from human aspirates in newborn infants fed with human milk. This highlights the importance of setting a relevant pH for these models. A static infant model was used by Dupont and co-workers to compare the *in vitro* digestion of dietary proteins with an adult model.⁵⁰ This model from Dupont and co-workers has also been applied in combination with the Infogest protocol to study the digestion of processed dairy proteins (glycated or cross-linked) as infant formula models under infant GI conditions.⁵¹ The average gastric pH used in these studies was relatively low, pH = 3, and it was increased to pH 4 in an updated protocol to study the digestion of proteins in infant formulas.⁵² Nevertheless, lipolytic enzymes were not included in this protocol despite the presence of lipids in the food matrix. A gastric model was developed to compare the digestion of milk protein solutions under static pH (2.5) and dynamic pH for adult and infant conditions.⁵³ Since the pepsin levels used for adult and infant conditions were very similar (240 and 210 U mg⁻¹ protein, respectively), proteolysis results were only different under dynamic pH conditions. In a following study, the same research group mimicked the gastric phase with dynamic pH and added a subsequent static intestinal phase to study proteolysis of Maillard products under infant and adult conditions.⁵⁴ The level of gastric and intestinal enzymes and bile acids were those used previously by Dupont and co-workers.⁵⁰ Dall'Asta and co-workers modified the adult *in vitro* model from Versantvoort *et al.*⁵⁵ to simulate infant GI conditions to digest human milk.⁵⁶ Although the model was suitable for real food matrices, and used a relevant gastric pH of 4.5 and pancreatic enzymes concentration, the levels of pepsin included were 10 times lower than those expected for infants. Another infant static digestion protocol was used by Klitgaard and co-workers, based on *in vivo* data reviewed in the literature,⁴⁴ to assess drug solubility and bioaccessibility *in vitro* under different conditions, *e.g.* fed versus fasted.⁵⁷ The model was well-designed in terms of relevant physicochemical parameters, however the gastric lipase used was from microbial origin (*Rhizopus oryzae*). Although this lipase has been widely used for *in vitro* gastric lipolysis, it is not recommended if rabbit gastric lipase is already commercially available. *Rhizopus oryzae* lipase has been shown to lead to more extensive *in vitro* gastric lipolysis of infant formulas (46–49%) as compared to human recombinant gastric lipase and rabbit gastric lipase (10–21%), which replicate both the

extent and functionality found *in vivo* (4.6–14.4%).⁴² This different behaviour between microbial and mammal source of gastric lipase is in part due to its different fatty acid chain length specificity.⁴² A static infant protocol considering GI digestion of infant formula has recently been developed based on *in vivo* data at gastric emptying half-time from literature as a first step towards consensus.³⁵ The parameters of the GI conditions of this infant model are summarised in Table 1 for comparison with adult standard models. This model is intended to simulate 28 days old full-term newborn and includes gastric lipase from rabbit gastric extract. In addition, the presence of reduced pancreatic amylase (in pancreatin) will compensate for the absence of salivary amylase as explained above. According to the authors, the duration of each phase may need to be extended or checked for alternative protein sources, *e.g.* plant. In addition, the model could be extrapolated to older infants by considering the level of maturity of the enzymes. This model was recently applied to study the micelle formation of carotenoids in human milk at different lactation period (colostrum versus mature milk).⁵⁸ In general, the infant static protocols have shown limited proteolysis in protein solutions or infant formulas^{35,50,54} and lower extent of intestinal lipolysis in infant formula as compared to adult models,³⁵ as observed *in vivo*. This is related to the reduction in enzyme activity (8-fold for pepsin and 6 to 10-fold for pancreatic enzymes: trypsin, chymotrypsin and lipase) and bile acids levels (4 to 10-fold).^{35,50,54} More sophisticated dynamic models of infant digestion will be discussed in following sections.

What is clear is that there is a need to develop harmonised static infant protocols targeted for different stages, *e.g.* 0–3, 3–6 months, since the infant conditions also vary largely with postnatal age and pre-term newborns should be differentiated from full-term newborns.³⁸ This may have caused discrepancies in the GI parameters of infant models reviewed in the literature.³⁹ These models would be useful in screening of structural/compositional parameters of new infant formulas (*e.g.* ultrastructure of emulsion, effect of processing, *etc.*) that could have important implications for digestion and absorption of nutrients in infants and in the performance of oral drug delivery.^{35,38}

2.2.2 Elderly digestion protocols. To date, there are no standard protocols of *in vitro* digestion for the elderly, despite the growing interest in developing functional foods with improved nutrient bioaccessibility for the elderly population.⁵⁹ The alterations in the GI tract due to ageing decrease the ability to provide the optimum level of nutrients. Gastrointestinal conditions in the elderly, not only comprise higher average gastric pH, lower levels of GI enzymes and a reduction in bile secretions, but also more concentrated saliva with higher levels of salivary amylase.⁵⁹ Pepsin secretions (basal and stimulated) have been reported to decrease 4-fold (between 70 and 90 years).⁶⁰ The first model targeted for the elderly (70–75 years old) was developed by Levi and Lesmes with a dynamic *in vitro* protocol for liquid protein-based formulations built on human physiological data in the GI tract of



seniors.³⁶ A subsequent study by these authors also accounted for lipid digestion in liquid formulations.³⁷ The representative parameters of this dynamic model have been included in Table 1 for comparison with the other static models. The gastric pH was set as the pH at the emptying half-time, which also coincides with the mean value of the gradient, for direct comparison with the other models. One can see that the average GI conditions for elderly are intermediate to those in infants and healthy adults in the fed state. The TIM dynamic model was for the first time adapted to reproduce elderly GI conditions (>65 years old) to follow digestion of proteins in cooked meat.⁶¹ Further details on these dynamic models for the elderly will be discussed below. The models set a good starting point to develop a harmonised elderly static digestion model suitable for liquid or solid food. An additional matter to discuss is the proper simulation of the oral chewing of solid foods for specific elderly population with deficient mastication. This is physiologically relevant as deficient mastication has been shown to give rise to larger particle size within the oral food bolus, which may affect subsequent macronutrient digestion in the gastric compartment.⁶²

Given the static nature of these models, the inherent limitations are the inability to replicate the dynamics of biochemical secretions, gastrointestinal emptying and motility, digesta absorption, hormonal responses, *etc.* Thus, the dynamics parameters obtained from these *in vitro* digestion models, such as the rate of digestion, are not physiologically relevant. It must be considered that the pH gradients within the GI tract, the buffering capacity of the food substrate, the gradual release of enzymes, the gastric sieving and emptying, and the removal of digestion products in the small intestine are likely affecting the kinetics of *in vitro* digestion and will be explained in more detail in following sections. However, the end-point results in the gastric and intestinal phase simulated with the Infogest protocol have shown good agreement with *in vivo* data for milk proteins.¹⁵

2.3 Semi-dynamic *in vitro* digestion models

Some digestion models classified as semi-dynamic can simulate at least one of the dynamic features of the GI tract. It is an intermediate system between the complex dynamic models and the simpler static models. Table 2 shows a list of studies in which a semi-dynamic model was used, illustrating the key parameters and applications.

The semi-dynamic models have been mainly used in reference to the gastric phase, simulating the chyme pH and/or the controlled enzymatic release. There are studies that have combined gastric digestion with the simulation of oral and/or intestinal phases but in a static manner. The semi-dynamic models are usually performed in a single simple vessel in contrast to the complex computer-controlled compartments of digestion used in the dynamic models. Most of the studies found in the literature that used some type of semi-dynamic model have focussed on the simulation of the dynamic changes in gastric pH. *In vivo* studies have shown that meal consumption causes a rapid increase in gastric pH from the

fasted pH of around 2 to a pH of 4.5–6.7 within 15 min, following of a steady pH decrease due to gradual HCl secretion.^{63,64} The main unit for pH control used in these studies is a pH-stat device, which can usually control both pH and fluid secretion. The pH-stat methodology is simple to use and available in most of the laboratories, and allows a computer-controlled auto-titration to simulate the gradient gastric pH profile observed *in vivo*.^{63,64}

The gastric pH can have a considerable impact on the kinetics of nutrient digestion, especially of proteins. The influence of gastric pH profile on digestion was studied in mixtures of β -lactoglobulin and xanthan gum gels by Dekkers and co-workers.⁶⁵ Two dynamic gastric pH profiles (initial pH of 6.0 *vs.* 5.2 and HCl secretion rates of 60 *vs.* 36 mmol h⁻¹) were compared with a fixed gastric pH (1.9). It is important to mention that the pH changes were based on data from previous studies *in vivo*. The study by Dekkers and co-workers showed significantly more protein hydrolysis during the first 30 min in the static pH digestion compared to the dynamic pH profile digestions. However, all three pH profiles provided similar extent of digestion after 90 min. Therefore, the static digestion induced the overestimation of pepsin activity during gastric phase. Protein hydrolysis in the stomach is performed by pepsin, whose activity is pH dependent and has a maximum at pH 1.5–2.5.⁴³ Similarly, Liu and co-workers showed slower protein digestion of α -lactalbumin when using semi-dynamic and dynamic models, compared to a static model (pH 3).⁶⁶ However, the lag phase in the dynamic system was a bit longer than that in the semi-dynamic model. This was suggested to be due to the high force of stirring of the semi-dynamic system whereas the mixing in the dynamic system led to a more heterogeneous pH environment in the body of the simulated stomach.

The changes in gastric pH can also affect protein conformation and structure, which will influence proteolytic susceptibility, the kinetics of protein digestion and gastric emptying.⁶⁷ Mulet-Cabero and co-workers investigated the behaviour of the main milk proteins, *i.e.* caseins and whey proteins, during gastric digestion performed by a semi-dynamic model simulating the dynamic pH profile, gradual secretion of enzyme and gastric fluids, and gastric emptying.⁶⁷ The authors showed that micellar caseins coagulated in the gastric conditions forming hard clots persisting during gastric digestion whereas whey proteins formed soft flocs that were not visible at the end of the gastric digestion. This study confirmed that the gastric behaviour of the milk proteins was the limiting factor of their protein digestion and absorption in the small intestine. This finding relates to the concept of ‘slow’ and ‘fast’ proteins corresponding to caseins and whey proteins, respectively, as observed in the rate of amino acids (AAs) appearance in plasma of an *in vivo* study.⁶⁸

The digestion of other macronutrients is also affected by the gastric pH changes. Shani-Levi *et al.* showed that oil-in-water emulsions stabilised by β -lactoglobulin and lactoferrin underwent several colloidal behaviours (destabilization, flocculation and coalescence) during gastric digestion using a





Table 2 Summary of studies using a semi-dynamic model

Study	Simulated dynamics	Control unit	Main body	Mixing mechanism	Temperature control	Digestion fluids	Food substrate tested	Application
Bourlieu <i>et al.</i> (2015) ⁴⁷	Gastric pH changes (from pH 6 to 4 for 180 min)	pH-Stat device	Vessel	NS	37 °C, water	- SGF electrolytes: 110 mM NaCl, 5 mM CaCl ₂ , 150 mM HCl - Rabbit gastric lipase (26 U mL ⁻¹) - Porcine pepsin (261.45 U mL ⁻¹)	Milk emulsion containing native milk fat globules and two processed model infant formulas (homogenized or homogenized/pasteurized)	Proteolysis and lipolysis kinetics, and structural changes in infant digestion
Shani-Levi <i>et al.</i> (2013) ⁵³	Gastric pH changes (adult: from pH 4.5 to 1.5 for 120 min, infant: from pH 6.5 to 3.5 for 240 min)	pH-Stat device	Vessel (cylindrical, 50–150 mL)	Rotational stirring (250 rpm)	37 °C, water	- SGF electrolytes: 2 g L ⁻¹ NaCl adjusted to pH 1.2 - Porcine pepsin (240 or 210 U mg ⁻¹ protein for adult or infant, respectively)	β-Lactoglobulin and lactoferrin solutions, and their emulsions using olive oil	Proteolysis kinetics in infant and adult digestion
Joubran <i>et al.</i> (2015) ⁵⁴								
Cohen <i>et al.</i> (2017) ⁷⁶							Maillard conjugates (α-lactalbumin with fructose or fructo-oligosaccharides)	Proteolysis kinetics to study antioxidant capacity
Dekkers <i>et al.</i> (2016) ⁶⁵	Gastric pH changes (profile A: from pH 6 to ~2, profile B: from pH 5 to 4, for 90 min)	- Syringe pump - pH module	NS	NS	NS	- SGF electrolytes: 2 mg mL ⁻¹ NaCl adjusted to pH 1.9 - Porcine pepsin (4.5 g mL ⁻¹)	β-Lactoglobulin-xanthan biopolymers gels	Protein digestion kinetics and gastric behaviour to study bioavailability and uptake of vitamin D
Liu <i>et al.</i> (2019) ⁶⁶	- Gastric pH changes (from pH 6.5 to 2 for 30 min) - Gradual enzyme secretion	- pH-Stat device - Syringe pump	Vessel	Rotational stirring (95 rpm)	37 °C, water	- SGF electrolytes: prepared as described by Minekus <i>et al.</i> (2014) ²⁰ but not pH adjusted - Porcine pepsin (2000 U mL ⁻¹)	α-Lactalbumin solution	Protein digestion kinetics and structural changes
Fahoum <i>et al.</i> (2017) ⁷⁷	Gastric pH changes (from pH 4.5 to 1.5 for 1 hour)	pH-Stat device	Cylindrical vessel (50–150 mL)	Rotational stirring (250 rpm)	37 °C, water	- SGF electrolytes based on Minekus <i>et al.</i> (2014) ²⁰ adjusted to pH 4.5 - Porcine pepsin (2000 U mL ⁻¹)	κ-, λ-, γ-carrageenan mixed with milk, soy or egg protein isolates	Protein hydrolysis kinetics
Stübler <i>et al.</i> (2019) ⁷⁸							Kale juice and strawberry puree and a blend of them	Protein hydrolysis to study protein-polyphenol stability
Aarak <i>et al.</i> (2013) ²⁸	Gastric pH changes (from pH 6.5 to 2.5 for 30 min)	pH-Stat device	Vessel	NS	37 °C, water	- SGF electrolytes: 0.15 M NaCl, pH: 6.5 - Phosphatidylcholine, 0.17 mM - Porcine pepsin (170 U mg ⁻¹ protein substrate)	Cooked salmon, broccoli and barley (stimulating a main dinner course)	Lipid and protein digestion, and digesta viscosity kinetics.
van Aken <i>et al.</i> (2011) ⁷⁹	- Gastric pH changes (0.2 mL min ⁻¹ of 0.03 M HCl for 60 min) - Gradual enzyme secretion	NS	Vessel (cylindrical, 150 mL)	Rotational stirring, 260 rpm	37 °C, water	- Porcine pepsin (902 U mL ⁻¹) - Fungal lipase (12 U mL ⁻¹)	Oil-in-water emulsion (stabilised by whey protein and Tween 80) and homogenized full fat milk	Gastric behaviour, and protein and lipid distribution after gastric digestion
Ferreira-Lazarte <i>et al.</i> (2017) ⁸⁰	- Gastric pH changes (to reach pH 2 for 2 hours) - Gradual enzyme and simulated fluids secretion	- pH-Stat device - Syringe pump	Vessel (v-shape, 70 mL)	Orbital stirring	37 °C, water	- SGF electrolytes based on Minekus <i>et al.</i> (2014) ²⁰ adjusted to pH 7 - Porcine pepsin (2000 U mL ⁻¹)	Skim milk powder with prebiotic carbohydrates	Carbohydrate and protein hydrolysis



Table 2 (Contd.)

Study	Simulated dynamics	Control unit	Main body	Mixing mechanism	Temperature control	Digestion fluids	Food substrate tested	Application
Mulet-Cabero <i>et al.</i> (2017) ⁷⁴	- Gastric pH changes (to reach pH 2, time depending on caloric density of food)	- pH-Stat device	Vessel (v-shape, 70 mL)	Orbital stirring	37 °C, water	- SGF electrolytes based on Minekus <i>et al.</i> (2014) ²⁰ adjusted to pH 7	Semi-solid meal (mixture of cheese and yogurt) and liquid meal (oil-in-water emulsion stabilised by milk proteins)	Gastric behaviour and protein and lipid hydrolysis kinetics
Mulet-Cabero <i>et al.</i> (2019) ⁶⁵	- Gradual enzyme and simulated fluids secretion	- Syringe pumps				- Porcine pepsin (2000 U mL ⁻¹)	Bovine whole milk with different industrial processes (pasteurisation, ultra-high temperature sterilisation and homogenisation)	Gastric behaviour, lipid released and protein hydrolysis kinetics
Mulet-Cabero <i>et al.</i> (2020) ⁶⁷	- Gastric emptying					- Gastric lipase, 40 U mL ⁻¹ (from rabbit gastric extract), added in Mulet-cabero <i>et al.</i> 2017 ⁷⁴)	Protein mixtures solutions with different casein : whey protein ratios, and inclusions of rapeseed oil	Gastric behaviour, lipid released and protein hydrolysis kinetics
van den Braak <i>et al.</i> (2013) ⁷⁰	- Gastric pH changes (from pH 6.6 to 2 for 100 min)	Computer-controlled pumps, pH sensors	8 bioreactors (cylindrical)	Rotational stirring (400 rpm)	37 °C, water	- SGF electrolytes: 50 mM NaCl, 15 mM KCl, 1 mM CaCl ₂ ·H ₂ O, 15 mM NaHCO ₃	Soy, pea, whey protein isolates and calcium caseinate, and a blend of them.	Gastric behaviour
Luiking <i>et al.</i> (2016) ⁸¹	- Gradual secretion of enzymes and simulated fluids					- Porcine pepsin 0.014% (w/v)	Whey protein isolate (leucine-enriched) and calcium caseinate with lipids and carbohydrates	Protein digestion kinetics
						- Gastric lipase (<i>Rhizopus oryzae</i>) 0.019% (w/v)		
						- Artificial saliva (0.1 M NaCl, 30 mM KCl, 2 mM CaCl ₂ , 15 mM NaHCO ₃ , 0.065% (w/v) α-amylase)		
Bicompartmental Levi <i>et al.</i> (2014) ⁶⁶	- Gastric pH changes	- Software programmes ("my-control" and "BioXper")	2 vessels (cylindrical, 250 mL)	Rotational stirring, pulsating (gastric) and constant (duodenal)	37 °C	- Simulated gastric, duodenal and bile fluids containing different concentration of the following salts: KCl, KH ₂ PO ₄ , NaHCO ₃ , NaCl, MgCl ₂ (H ₂ O) ₆ , NH ₄ Cl, NaH ₂ PO ₄ (H ₂ O) ₂ , urea and CaCl ₂ (H ₂ O) ₂ .	β-Lactoglobulin, α-lactalbumin and lactoferrin solutions	Protein digestion kinetics in the elderly and adult digestion conditions
Levi <i>et al.</i> (2017) ³⁷	- Gastric emptying - Duodenal pH - Bile secretion gradient	- Peristaltic pump - pH sensors				- Porcine pepsin 1000 (adults) or 750 U mL ⁻¹ (the elderly) - Gastric lipase (from rabbit gastric extract) 1500 (adults) or 255 U mL ⁻¹ (the elderly). - Porcine trypsin 100 (adults) or 46 U mL ⁻¹ (the elderly), chymotrypsin 50 (adults) or 23 U mL ⁻¹ (the elderly). - Bile salts: sodium glycodeoxycholate and taurocholic acid sodium salt hydrate, 4 (adults) or 2.67 mM (the elderly) - Porcine pancreatin lipase 2000 (adults) or 1400 U mL ⁻¹ (the elderly) - Porcine α-amylase 150 (adults) or 300 U mL ⁻¹ (the elderly) - Mucin from porcine stomach 0.05 g L ⁻¹	β-Lactoglobulin, α-lactalbumin and lactoferrin solutions and, commercial liquid formula (proteins, lipids, carbohydrates and vitamins)	Protein digestion kinetics and generation of bioactive peptides in the elderly and adult digestion conditions

SGF: simulated gastric fluid, NS: not specified.

dynamic pH profile, compared to the static profile.⁵³ Similarly, Mulet-Cabero and co-workers observed different colloidal behaviours during the gastric phase of bovine whole milk with different industrial processing, *i.e.* homogenisation, pasteurisation and ultra-high temperature (UHT) sterilisation.⁶⁹ The homogenised samples presented the formation of an upper lipid layer, which delayed the subsequent emptying of lipids. However, neither of these two studies used gastric lipase, which could influence the gastric digestion and behaviour of lipids. The availability of relevant gastric lipases, such as rabbit gastric extract, has been recently improved. This will allow the investigation of the effect of dynamic gastric pH on lipid digestion, which involves gastric lipase having a different pH optimum compared to pepsin.¹⁰ For instance, using rabbit gastric extract, Bourlieu and co-workers showed that the structural parameters of the infant milk formulas tested were a limiting factor to control gastric lipolysis and the patterns of fatty acids released, when using a dynamic gastric pH based on infant digestion conditions.⁴⁷

The conditions of digestion in the GI tract vary significantly between age populations *i.e.* infants, adults and the elderly.³⁹ This includes pH gradient, enzymatic levels and gastric emptying rates. These differences can lead to changes in the hydrolysis of food nutrients. Some of the reported semi-dynamic models have been adapted to simulate the digestion of other age groups, apart from adults. For example, *in vivo* data has been used to adjust the pH gradient to simulate the digestion of infants^{47,53} and the elderly digestion.³⁶ One of the advantages of the semi-dynamic model is that it can be easily adapted to other parameters of digestion, such as pH, since they do not usually involve complex software. However, there are also more advanced semi-dynamic models. Shani-Levi and co-workers used a bi-compartmental system, two reactors connected, simulating the gastric and duodenal phases.³⁶ In this model, a computer controls the temperature, the different secretions and the gastric emptying. This bi-compartmental model was used to simulate the digestion of both adult and the elderly using *in vivo* parameters specific to the relevant age. The digestive fate of protein was determined in some milk protein solutions (β -lactoglobulin, α -lactalbumin and lactoferrin) to assess the efficacy of the system and compare the two sets of digestion conditions. As seen in Table 2, the model uses complex digestion fluids, individual enzymes and bile salts. Using the same semi-dynamic bi-compartment system, the use of gastric lipase from rabbit gastric extract in a dynamic gastric pH profile led to differences in the colloidal gastric phase.³⁹ The state of coalescence was observed under adult conditions while flocculation was dominant under elderly conditions. This behaviour could have affected the subsequent protein digestion in the duodenum as seen by the generation of different bioactive peptides. Another sophisticated semi-dynamic model consists of eight parallel computer-controlled bioreactors, offering high throughput capabilities.⁷⁰ Each unit is equipped with a pH electrode and four pumps with dosing-lines (1 M HCl and 1 M NaHCO₃ and 3 M NaOH, for pH adjustment, simulated gastric juice and simulated

saliva). During the digestion, both simulated saliva and gastric fluids were added gradually. This model was applied to some plant proteins (pea and soy) to assess their gastric behaviour compared to whey proteins and sodium caseinate.

The use of a semi-dynamic simulation for studying gastric behaviour needs to consider the mixing mechanism carefully. Most of the semi-dynamic models discussed used rotational stirring using, usually, a magnetic stirrer. This probably disrupts the formation of any possible structural changes within the simulated stomach. The aim of the mixing in this model should be to disperse the acid solution that is secreted over time. This does not mean that the pH needs to be homogenous within the compartment. Indeed, the human intra-gastric pH is heterogeneous and the chyme is not distributed homogeneously within the stomach.⁷¹ In addition, the shape of the simulated stomach should be considered since it can influence the shear forces. The stomach is a J-shaped organ and the construction of this kind of shape can be difficult. The cylindrical shape vessel is the most common shape used in the present semi-dynamic models. However, a V-shape vessel has been used,⁶⁷ which simulates the inverted cone shape observed in some dynamic models such as the dynamic gastric model⁷² and the human gastric simulator.⁷³

The semi-dynamic model has been seen of relevance to gain more insight into the digestion of food that is susceptible to pH change and obtain kinetics of protein digestion. However, as seen in Table 2, the parameters in which digestion is performed vary from one study to another and even in the same research group. In addition, some of the parameters such as enzyme source and activities, and mixing have not been described or clearly specified. In order to allow comparison, a standardised protocol for a semi-dynamic model has been recently developed.²¹ The authors provide a detailed description of how to perform this semi-dynamic model, which includes crucial kinetic aspects associated with the gastric phase of digestion, including gradual acidification, fluid and enzyme secretion and emptying. Static small intestinal digestion of the aliquots that are collected over time simulating the gastric emptying can be used to evaluate the kinetics of nutrient bioaccessibility. Adaptations of this model have already been used to provide kinetic data on nutrient digestion and structural changes during the gastric phase, which influenced nutrient absorption.^{67,69,74} Moreover, it provides a simple tool that can be used in a wide range of laboratories.

In conclusion, the semi-dynamic model provides a simple approach to perform a more physiologically relevant simulation of the gastric phase, by which digestion kinetics can be obtained. It could help to provide new and more physiologically relevant insights into protein and emulsion gastric behaviour, which is crucial in the understanding of the kinetics of nutrient bioavailability and absorption. For instance, by the simulation of the gastric emptying, the degree of digestion of the initial fractions leaving the stomach may have a great influence in the neuro-hormonal regulation of the subsequent gastric emptying.⁷⁵ It requires simple and widely accessible devices, which allows its use in many laboratories. It is much



less expensive than dynamic models since it is based on small volumes, therefore, the amount of enzymes needed is less. However, running this model is more time-consuming and a lower throughput system, compared to the static model. Furthermore, the gastric emptying may be difficult with some foods, especially solids.

2.4 Dynamic *in vitro* digestion models

Dynamic model systems are designed to mimic a series of variable factors of the GI tract, such as the secretion of digestion fluids, variable enzyme concentration, pH changes, the transit of chyme and the appropriate mixing at each stage due to peristalsis. Because of these characteristics, they can provide a meaningful mechanistic understanding of food digestion by assessing the nutrient bioaccessibility rate and extent. A few dynamic *in vitro* models have been developed in comparison to static models. Dynamic models can be mono-compartmental, bicompartamental or multicompartmental, which simulates one, two and several compartments of the digestive tract, respectively. The use of the different models will depend on the purpose of study. In this section, the specific mouth simulators and colon models will not be discussed but have been reviewed elsewhere.^{82,83}

2.4.1 Mono-compartmental systems. Most of the mono-compartmental dynamic models have been proposed for the simulation of the stomach. There are also a few models dedicated to the small intestine such as the dynamic duodenal model⁸⁴ and human duodenum model.⁸⁵ This section is focussed on the models mimicking the stomach since they are more widely used. The characteristics and applications of two mono-compartmental models, as described below, aim to serve as example of the relevance of this model. Table 3 shows a summary of the main characteristics of the models emphasising on their applications and the variety of foods tested.

The dynamic gastric model (DGM). The DGM was developed at the former Institute of Food Research (Norwich, UK).⁸⁶ It is a computer-controlled single compartment with an inverted cone shape, made of latex and capacity of ~800 mL. Within the fundus/main body of the DGM, the acid and enzyme fluids are secreted depending on the food composition. The rate of acid secretion is controlled by the pH response of the food sample. The mechanical forces are applied by water (kept at 37 °C) pressure with a piston and barrel, and differ in the main body and the antrum. In the main body of the DGM, the bolus is subjected to gentle peristaltic contractions (three contractions per minute). Portions of gastric contents are moved into the antral part and subjected to high shear stress and mixing. There is also the addition of an initial gastric basal volume. The gastric residence time is calculated by the software associated with the DGM and depends on the meal size, composition and caloric content. The emptying is set at pre-defined intervals and after emptying, samples may be subjected to further digestion depending on the purpose of the study. The efficiency of the antral mechanical forces were calibrated by studying the breakdown of agar beads of various fracture strengths in high- and low-viscosity meals.⁸⁷ The

results obtained from the DGM were comparable to those reported in a human study using similar meals.⁸⁸

The DGM has been extensively used for food-based research. The system allows the use of complex and realistic food matrices, as used in *in vivo* studies. It has widely been used to assess the hydrolysis rate and extent of macronutrients and bioactives in the GI upper tract through the rate of nutrient released from the gastric digestion. The effect of food matrix and processing has been mainly investigated. In addition, the study of the structural changes during the digestion has been performed using microscopy to gain more insight into the mechanisms of food structure on nutrient delivery and nutrient interactions. For instance, the *in vitro* study of the lipid digestion in almonds is important to understand the mechanisms by which the consumption of almonds can reduce a number of risk factors associated with non-communicable diseases such as obesity.⁸⁹ The effect of processing (roasting) and mastication on the lipid bioaccessibility of almonds was studied using the DGM followed by static small intestine digestion.⁹⁰ In addition, the effect of the almond particle size in a muffin matrix was investigated.⁹¹ These studies have concluded that the cell wall in almonds governs the lipid digestion and therefore give plausible mechanisms of the physiological responses observed after the consumption of almonds. The effect of the food matrix was also studied in the protein digestion and immunoreactivity of polypeptides from almond flour,⁹² which provides insight into the interrelationship between food matrix and almond allergy. The DGM was used to assess the GI digestion of starch in different cereals to provide mechanisms associated with glycaemic response.⁹³ The DGM has also been used to study the bioaccessibility kinetics of other bioactives. The release of polyphenols and tocopherols from pistachios, with different processing and in the presence of food matrix (muffin), was assessed during GI digestion.⁹⁴ This research highlights the relevance of the food matrix in the uptake of beneficial bioactives. The DGM has also been used to study probiotic survival in the GI tract.⁹⁵

The limitations of the model include the vertical orientation of the gastric compartment, which differs from that *in vivo*, which might affect the simulation of fluid dynamics and distribution of gastric contents. The compartment is not transparent, which does not allow visual observations during digestion. Moreover, it is open from the top exposed to air, which might lead to pH fluctuations.

The human gastric simulator (HGS). The HGS was created at the University of California (USA) and also reproduced at the Riddet Institute (New Zealand).⁷³ The stomach compartment is simulated by a cylindrical flexible chamber made of latex in an inverted conical shape and capacity of about 5.7 L. The delivery of gastric secretion is controlled by a peristaltic pump and usually set at the rate of 2.5 mL min⁻¹. Gastric emptying is performed by a peristaltic pump connected to the bottom of the gastric compartment with a mesh bag (pore size ~1.5 mm) placed inside the chamber to mimic the human gastric sieving. The rate of gastric emptying is usually set at 3 mL min⁻¹ and the time of gastric digestion varies from 3 to





Table 3 Examples of extensively cited mono-compartmental dynamic systems, DGM and HGS

System	Photo	Simulated dynamics	Digestion fluids	Application	Food substrate tested	Ref.
Dynamic gastric model (DGM)		<ul style="list-style-type: none"> - Gastric pH changes - Gradual enzyme secretions - Peristaltic contractions - Gastric emptying and sieving 	<ul style="list-style-type: none"> - Electrolytes (0.2 M HCl, 0.08 M NaCl, 0.03 mM CaCl₂, 0.9 mM NaH₂PO₄) - Shelled lecithin liposomes (0.127 mM) - Pepsin (9000 U mL⁻¹, porcine) - Gastric lipase (60 U mL⁻¹, fungal, <i>Rhizopus oryzae</i>) (conditions from Curro <i>et al.</i> 2011⁹⁵) 	<ul style="list-style-type: none"> Bioaccessibility kinetics of bioactives (polyphenols, carotenoids) - Extent of lipid hydrolysis - Structural changes Hydrolysis kinetics of protein - Hydrolysis kinetics of starch - Structural changes Hydrolysis kinetics of starch and protein Physical disintegration kinetics Lipid stability, protein hydrolysis and digesta microstructure Physical disintegration kinetics and rheology properties of gastric digesta Gastric structural changes and protein hydrolysis kinetics Gastric structural changes, protein/lipid release kinetics, and digesta microstructure Gastric structural changes, protein hydrolysis kinetics and digesta microstructure Gastric structural changes, protein hydrolysis kinetics, lipid release kinetics and digesta microstructure 	<ul style="list-style-type: none"> Raw, toasted pistachios, and muffins with raw pistachios Biscuits, crisp-bread and full-fat milk with almond skins Edible agar film with green tea extract Raw and roasted almonds Muffins with small or large almond particles Chocolate mouse and Victoria sponge cake made with almond flour White bread, cornflakes, micronized barley and extruded barley flakes, oat flour and extruded oat flakes Extruded snack with blends of wheat flour and (native/hydrolysed) pea protein Porridge meal with flour (different particle size) and semolina (different particle size) Emulsion (whey protein and soybean oil) gels. Hard vs. soft Cooked white and brown rice Skim milk (unheated vs. heated, 90 °C for 20 min) Whole milk (untreated/homogenised/homogenised + heated) Milk protein ingredients (skim milk powder, milk protein concentrate, calcium-depleted milk protein concentrate, sodium caseinate, whey protein isolate (unheated, heated at 90 °C for 20 min)) Oil-in-water emulsions stabilised by milk protein ingredients (milk protein concentrate, calcium-depleted milk protein concentrate, sodium caseinate) Oil-in-water emulsions stabilised by whey protein isolate. Unheated vs. heated (90 °C, 20 min) 	<ul style="list-style-type: none"> Mandalari <i>et al.</i> (2013)⁹⁴ Mandalari <i>et al.</i> (2016)¹⁰⁵ Lopez de Lacey <i>et al.</i> (2012)¹⁰⁶ Mandalari <i>et al.</i> (2014)⁹⁰ Grassby <i>et al.</i> (2017)⁹¹ Mandalari <i>et al.</i> (2014)⁹² Ballance <i>et al.</i> (2013)⁹³ López-Barón <i>et al.</i> (2018)¹⁰⁷ Mandalari <i>et al.</i> (2018)¹⁰⁸ Guo <i>et al.</i> (2015)¹⁰¹ Guo <i>et al.</i> (2014)¹⁰⁰ Kong <i>et al.</i> (2011)⁹⁸ Ye <i>et al.</i> (2016)¹⁰² Ye <i>et al.</i> (2016)¹⁰³ Ye <i>et al.</i> (2017)¹⁰⁴ Wang <i>et al.</i> (2018)¹⁰⁹ Wang <i>et al.</i> (2019)¹¹⁰ Ye <i>et al.</i> (2020)¹¹¹
Human gastric simulator (HGS)		<ul style="list-style-type: none"> - Gastric pH changes - Gradual gastric secretions - Gradual gastric emptying in a set time and sieving - Continuous peristaltic contractions and antrum forces 	<ul style="list-style-type: none"> - Electrolytes: NaCl (8.775 g L⁻¹), adjusted to pH 1.3 - Pepsin (1 g L⁻¹, porcine) - Gastric mucin (1.5 g L⁻¹) (conditions from Kong <i>et al.</i> 2010⁷³) 	<ul style="list-style-type: none"> Physical disintegration kinetics Lipid stability, protein hydrolysis and digesta microstructure Physical disintegration kinetics and rheology properties of gastric digesta Gastric structural changes and protein hydrolysis kinetics Gastric structural changes, protein/lipid release kinetics, and digesta microstructure Gastric structural changes, protein hydrolysis kinetics and digesta microstructure Gastric structural changes, protein hydrolysis kinetics, lipid release kinetics and digesta microstructure 	<ul style="list-style-type: none"> Skim milk (unheated vs. heated, 90 °C for 20 min) Whole milk (untreated/homogenised/homogenised + heated) Milk protein ingredients (skim milk powder, milk protein concentrate, calcium-depleted milk protein concentrate, sodium caseinate, whey protein isolate (unheated, heated at 90 °C for 20 min)) Oil-in-water emulsions stabilised by milk protein ingredients (milk protein concentrate, calcium-depleted milk protein concentrate, sodium caseinate) Oil-in-water emulsions stabilised by whey protein isolate. Unheated vs. heated (90 °C, 20 min) 	<ul style="list-style-type: none"> Guo <i>et al.</i> (2015)¹⁰¹ Guo <i>et al.</i> (2014)¹⁰⁰ Kong <i>et al.</i> (2011)⁹⁸ Ye <i>et al.</i> (2016)¹⁰² Ye <i>et al.</i> (2016)¹⁰³ Ye <i>et al.</i> (2017)¹⁰⁴ Wang <i>et al.</i> (2018)¹⁰⁹ Wang <i>et al.</i> (2019)¹¹⁰ Ye <i>et al.</i> (2020)¹¹¹

5 hours. The system is operated at 37 °C using a heater and fan. It has a series of rollers supported by belts controlled by a variable speed motor. The rollers compress the simulated stomach wall with an increasing amplitude (set usually at three contractions per minute). The compression forces are higher on the bottom of the compartment as the rollers come closer, which increases the amplitude and mimic the antral contractions. The HGS was designed aiming to closely mimic the peristaltic activity of the antrum contractions waves and, thus, provide a physiologically relevant range of amplitude and frequency of mechanical forces as those presented *in vivo*. The performance of the HGS was evaluated by digesting cooked rice and apple slices in the simulated stomach. The maximum stresses recorded within the HGS were 6738 N m⁻² and 8922 N m⁻², for 50% and 70% of compression, respectively. This is, according to the authors, in good agreement with *in vivo* data that reported mechanical stresses varying from 5134 to 67 292 N m⁻² (ref. 88 and 96) and the comparison of the contraction force profile.⁹⁷

The HGS has been widely used in the research of food materials. The main applications have been to investigate the effect of physical breakdown and gastric stability during digestion on nutrient release kinetics. This research is of high relevance to understand the mechanisms of the physiological responses of foods. For instance, the physical digestion of brown and white rice was studied using the HGS.⁹⁸ It was shown that the bran layer on brown rice limited the physical disintegration of the rice, delaying the gastric emptying and, as a result, the possible starch digestion. This research has offered a plausible mechanism by which some human studies showed that brown rice lowered glycaemic responses when compared to white rice.⁹⁹ The disintegration kinetics in the stomach are of crucial relevance to assess the nutrient bioaccessibility in the small intestine. The consistency of the matrix in which the nutrients are confined governs the released of proteins and lipids, and their gastric emptying. This was investigated using emulsion gels with different hardness digested in the HGS.^{100,101} The dynamics of the HGS provided the structural changes during gastric digestion of milk, forming a structured clot. This restructuring impacted protein hydrolysis¹⁰² and lipid released¹⁰³ during gastric digestion. Furthermore, this gastric behaviour was affected by the different milk processing treatments of homogenisation and heat.¹⁰⁴

The limitations of the HGS include the fact that the rates of gastric fluid secretion and emptying, as well as the time of residence, are not based on the properties of the food materials, which is not physiologically relevant. The HGS, similar to the DGM, does not provide a physiological shape of the stomach and the gastric contents depend on gravity. Additionally, the progression of the digestion cannot be observed *in situ* since the material of the compartment is not transparent.

2.4.2 Multi-compartmental models. The multi-compartmental models consist of the simulation of the kinetics of the GI tract in more than one compartment. This section discusses the models simulating the upper GI tract, *i.e.* stomach and small intestine. There are others multi-compartmental models

that have been applied for research on the large intestine even though they also contain gastric and small intestinal compartments, the simulator gastrointestinal (SIMGI)¹¹² and the simulator of the human intestinal microbial ecosystem (SHIME),¹¹³ which will not be discussed. Two of the main upper GI tract models are described below to expose the relevance of this model. Table 4 shows a summary of the main characteristics of the models emphasising on their applications and the variety of foods tested.

TNO's gastrointestinal model (TIM). The TIM was developed at TNO Nutrition and Food Research (The Netherlands).¹¹⁴ It consists of tubular compartments made of glass jackets (capacity of ~300 mL) with flexible inner wall that can be controlled independently. The conditions of digestion in each compartment, such as pH and secretion rates, are controlled by software based on *in vivo* studies in animals and human volunteers. Peristaltic pumps enable the transit of chyme between compartments. The programmable gastric emptying curve depends on type and amount of food, and follows Elashoff's equation, as well as the intestinal delivery. To imitate peristalsis, the tubes are squeezed periodically by a pump action on the surrounding water, which also maintains a physiological temperature (37 °C). It is usually applied 3 and 9 contractions per minute in the gastric and intestine compartment, respectively. Furthermore, the TIM allows the constant removal of digestive products and water by filtration and membrane dialysis to simulate the nutrient uptake in the small intestine.

Some TIM systems have been developed focussing on the upper GI tract; TIM-1, with a stomach compartment and three compartments for the small intestine, *i.e.* the duodenum, jejunum and ileum, and the tiny-TIM that consists of a stomach compartment and one single compartment for the small intestine. The accuracy and reproducibility of the model for gastric delivery, intestinal transit and ileal delivery of chyme were assessed in simulating a slow and fast transit time.¹¹⁴ For that, the data from human volunteers who consumed yoghurt and milk was applied, respectively, and a solution of blue dextran was used as a test meal. The efficacy of the model was assessed by testing the glucose levels in the dialyzed aliquots from the simulated ileum. The *in vitro* data from the digesta transit simulated closely the *in vivo* data.

The unique feature of the incorporated dialysis or filtration membrane systems allows the assessment of the rate at which the absorbable digestion products are generated. The TIM has been used for food-related studies to examine the bioaccessibility of nutrients and the stability of phytochemicals, providing mechanistic insights into some physiological responses of foods. For instance, dietary fibre has been shown to exert some specific physiological responses (*e.g.* reduced postprandial glycaemic response) and one of the mechanisms proposed is the increase of digesta consistency in the GI tract. The effect of the enrichment of biscuits in viscous soluble fibres, combined or not with protein, on the viscosity of the chyme was investigated throughout the different upper digestive compartments of the TIM-1 system.¹¹⁵ The results showed a significant





Table 4 Examples of studies using the multi-compartmental dynamic systems, TIM and DIDGI®



System	Photo	Simulated dynamics	Digestion fluids	Application	Food substrate tested	Ref.
TNO gastro-intestinal model (TIM-1)		<p><i>Gastric compartment:</i></p> <ul style="list-style-type: none"> - Gastric pH changes - Gradual enzyme secretion - Mixing - Gastric emptying and sieving <p><i>Small intestinal compartment:</i></p> <ul style="list-style-type: none"> - Controlled pH at pre-set values for each compartment - Gradual secretion of bile, intestinal electrolytes and pancreatic - Ileal emptying rate 	<p><i>Gastric compartment:</i></p> <ul style="list-style-type: none"> - Electrolytes: 1.1 g L^{-1} KCl, 3.1 g L^{-1} NaCl, 0.15 g L^{-1} CaCl₂, 0.6 g L^{-1} NaHCO₃ - Pepsin (porcine, 520 U min^{-1}) - Lipase (amano lipase, 7 U min^{-1}) From pH 6.2 to 2.3, for 240 min using 0.6 M HCl <p><i>Small intestinal compartment:</i></p> <ul style="list-style-type: none"> - Electrolytes: 5 g L^{-1} NaCl, 0.6 g L^{-1} KCl, 0.3 g L^{-1} CaCl₂·2H₂O - Bile salts (porcine, 20 mg min^{-1} for 30 min, then 10 mg min^{-1}) - Pancreatin (porcine, 89 mg min^{-1}) with 1% w/w pancreatic lipase 	<ul style="list-style-type: none"> Protein and starch digestion rate Viscosity kinetics of chyme - Starch hydrolysis rate - Digesta microstructure Glucose bioaccessibility rate - Viscosity kinetics of chyme - Glucose bioaccessibility rate 	<ul style="list-style-type: none"> Short-dough biscuits (enriched in proteins and/or fibre) Fermented barley and oat Tempe Rye products (sourdough-fermented bread, fermented and unfermented crispbread, extrusion-cooked rye, and porridge) Glucose and maltodextrin solutions Milk protein concentrate added to instant oats and steel cut oats Instant oats, steel cut oats and oat bran Oil-in-water emulsions with tricaprylin and nonionic surfactants (Tween-20, Tween-40, Tween-60, Span-20, Span-60, or Span-80) and anionic surfactants (sodium lauryl sulfate, sodium stearyl lactylate, and sodium stearyl fumarate) Salmon/whey protein hydrolysate Wheat fractions: aleurone, bran, flour or starch Rapeseed, sunflower seed, whole-wheat and white wheat flour β-Carotene from vegetable or supplemented β-carotene Blueberry and maqui berry extract (with and without a standardised high fat meal) Red or yellow tomato puree in a standard meal (western diet) Boiled, fried and scrambled eggs Breads from different wheat fractions (aleurone, bran and flour) UHT processed and pasteurised milk fortified with folic acid or 5-methyltetrahydrofolate 	<ul style="list-style-type: none"> Villemejane <i>et al.</i> (2016)¹¹⁶ Villemejane <i>et al.</i> (2015)¹¹⁵ Alminger <i>et al.</i> (2012)¹³³ Johansson <i>et al.</i> (2018)¹³⁴ Karhikeyan <i>et al.</i> (2019)¹³⁵ AlHasawi <i>et al.</i> (2018)¹³⁶ AlHasawi <i>et al.</i> (2017)¹¹⁷ Speranza <i>et al.</i> (2013)¹³⁷ Framroze <i>et al.</i> (2014)¹³⁸ Anson <i>et al.</i> (2010)¹³⁹ Larsson <i>et al.</i> (1997)¹⁴⁰ Van Loo-Bouwman <i>et al.</i> (2014)¹⁴¹ Lila <i>et al.</i> (2012)¹⁴² Blanquet-Diot <i>et al.</i> (2009)¹¹⁹ Nimalaratne <i>et al.</i> (2015)¹¹⁸ Anson <i>et al.</i> (2009)⁵ Verwei <i>et al.</i> (2003)¹⁴³

Table 4 (Contd.)

System	Photo	Simulated dynamics	Digestion fluids	Application	Food substrate tested	Ref.
DIDGI®		<p>Gastric compartment:</p> <ul style="list-style-type: none"> - Gastric pH changes - Gradual enzyme secretion - Gastric emptying and sieving <p>Small intestinal compartment:</p> <ul style="list-style-type: none"> - Controlled pH - Gradual secretion of bile, intestinal electrolytes and pancreatin 	<p>Gastric compartment:</p> <ul style="list-style-type: none"> - Electrolytes: Na^+ 100 mmol L^{-1}, Ca^{2+} 1 mmol L^{-1}, pH 6.5 - Pepsin (porcine, 2000 U mL^{-1}, 1 mL min^{-1} for 5 min then 0.5 mL min^{-1}) <p>Small intestinal compartment:</p> <ul style="list-style-type: none"> - Intestinal electrolytes: Na^+ 100 mmol L^{-1}, Ca^{2+} 100 mmol L^{-1}, pH 6.6 - Pancreatin (porcine, 7%, 0.25 mL min^{-1}) - Bile salts (bovine, 4% for 30 min then 2% (conditions from Menard <i>et al.</i> 2018¹⁴⁴)) 	<p>Protein hydrolysis kinetics</p> <p>Lipid digestion kinetics</p> <p>Starch hydrolysis kinetics</p> <p>In an infant digestion model</p> <p>- Kinetics of lipolysis and proteolysis</p> <p>- Structural changes</p>	<p>Bovine skim milk powder</p> <p>Heated and unheated bovine skim milk powder</p> <p>Liquid yoghurts (enriched in protein/fibre) with different viscosity</p> <p>Fat-free yogurt enriched with whey protein isolate emulsified safflower oil (in free emulsion or encapsulated with calcium-alginate beads)</p> <p>White bread, wheat-based and gluten-free pasta</p> <p>White bread with water, tea or lemon juice</p> <p>Human milk (pasteurised and raw)</p> <p>Infant milk formula</p>	<p>Egger <i>et al.</i> (2019)¹⁵</p> <p>Sánchez-Rivera <i>et al.</i> (2015)¹²⁶</p> <p>Ménard <i>et al.</i> (2018)¹⁴⁴</p> <p>Corstens <i>et al.</i> (2018)¹²⁸</p> <p>Freitas <i>et al.</i> (2019)¹²⁹</p> <p>Freitas <i>et al.</i> (2019)¹⁴⁵</p> <p>de Oliveira <i>et al.</i> (2016)¹²⁵</p> <p>Deglaire <i>et al.</i> (2016)¹⁴⁶</p> <p>Ménard <i>et al.</i> (2014)¹²⁴</p>

effect of the soluble fibres on the chyme viscosity during GI digestion. Using the same biscuits, the effects of enrichment in fibre and proteins on starch and protein hydrolysis was determined during the digestive process.¹¹⁶ These studies highlight the relevance of the effect of dietary fibre in a dynamic system, as well as the mechanisms driving the physiological responses and the limiting factors. Viscosity is one of the major physical properties of food having a major role in influencing the flow behaviour and gastric emptying rate, which can affect the rates of digestion, nutrient release and intestinal absorption. Real-time luminal viscosity in the simulated GI tract of TIM-1 was assessed using optical chromophores that exhibit molecular rotor behaviour.¹¹⁷ The physicochemical properties of three commercially available oat-based products (instant oats, steel cut oats and oat bran) were assessed on starch digestion. The authors showed that steel cut oats presented the slowest rate of starch digestion, which was linked to the gastric luminal viscosity.

The TIM-1 system has been widely used in the assessment of the bioaccessibility of different phytochemicals during digestion. This system has provided relevant information about the digestive stability of bioactives, especially at the level where degradation occurs throughout digestion, and about their sensitivity to the different factors of the GI digestion, in particular, the pH changes. The main effects tested are food matrix and processing. Some examples are the investigation of the effect of processing of eggs in the bioaccessibility of lutein and zeaxanthin,¹¹⁸ and the study of the bioaccessibility of zeaxanthin, lutein, β -carotene and lycopene in a standard meal with the addition of red or yellow tomato puree.¹¹⁹ The compartment of dialysis and membrane filtration for removal of low molecular compounds from the digestion is not able to simulate the absorption processes occurring *in vivo* such as active transport, efflux and intestinal wall metabolism. For that, TIM-1 samples can be combined with intestinal absorption systems to predict nutrient bioavailability. For instance, TIM-1 coupled with Caco-2 cells was used to assess the absorption of lycopene and α -tocopherol from a whole western-type meal containing puree of red tomatoes.¹²⁰ TIM-1 has been used as a relevant tool to assess the efficacy of drug delivery systems in the GI tract, providing also the effect of meal consumption on the drug uptake.¹²¹

Some limitations of the TIM are that many of the food matrices tested in the TIM-1 model do not present the complexity of those used in other dynamic models, such as the DGM. This could be due to the performance and shape of the gastric compartment. Therefore, the model could be limited in the study of the structure stability in the gastric phase. The intragastric behaviour and extent of lipolysis of various emulsions stabilised by different stabilisers was studied.^{122,123} For that, the authors used the tiny-TIM with a specifically designed gastric compartment. It consisted of a main body and lower antral part with an L-shape, in contrast to the tubular shape of the TIM-1. The authors showed that the extent of cream layer formation was the limiting factor for the delay in the entry of lipid into the small intestinal compartment and, hence, a



delay in absorption. This adaptation has been taken further resulting in the developed of the TIM advanced gastric compartment (TIMAge).

DIDGI®. The DIDGI® system was developed at INRAE, the French National Research Institute for Agriculture, Food and Environment.¹²⁴ It consists of two consecutive compartments simulating the stomach and small intestine (capacity of 200 mL). It is a computer-controlled system that simulates the pH changes and sequential addition of digestive secretions, applied by peristaltic pumps. Each compartment is surrounded by a glass jacket filled with water at 37 °C. Gastric emptying is performed using a peristaltic pump together with a 2 mm membrane. The digestion parameters such as the digestion time, pH curve, secretion and emptying rates are based on *in vivo* data from human volunteers and animals and supported by the StoRM computer software. The gastric and intestinal emptying are controlled based on the Elashoff's equation. The DIDGI® was validated by comparing the *in vitro* digestion of an infant milk formula with the *in vivo* data collected in 18 piglets.¹²⁴ The parameters of digestion such as pH curves and transit time were obtained using *in vivo* data related to infant physiological conditions. The chyme transit presented no significant differences, as observed in the remaining volumes in the gastric compartment, confirming the physiological relevance of the DIDGI® system. The proteolysis kinetics of the main milk proteins (caseins and β -lactoglobulin) in both gastric and small intestinal compartments were, in general, comparable between the *in vitro* dynamic and *in vivo* digestion.

The DIDGI® has mainly been used to study the digestion of dairy products/ingredients. Since it was primarily designed considering the infant digestion, some studies have focussed on the study of the protein and lipid digestion of human milk and infant milk formula. The effect of Holder pasteurisation (62.5 °C, 30 min) of human milk on the proteolysis and lipolysis kinetics, was compared to raw human milk.¹²⁵ The authors found differences in the susceptibility of proteolysis and intestinal release of some amino acids in the heated human milk. Pasteurisation also limited lipolysis but not the evolution of lipid classes. These differences could be linked to the structural changes observed during gastric digestion using microscopy. This study showed that the use of the DIDGI® could provide some understanding of the digestive kinetics of the human milk. The impact of heat treatment on the hydrolysis kinetics of milk proteins and peptide release has also been studied.¹²⁶ Bovine skim milk powder solution was heated at 90 °C for 10 min and gastric digestion was performed using the DIDGI® system. The half-time of gastric emptying used was set at 191 and 283 min for unheated and heated milk, respectively, as estimated in mini-pigs fed with the same milks.¹²⁷ The authors showed that the heat treatment applied induced an increase of the resistance of caseins and higher susceptibility of β -lactoglobulin upon digestion. Furthermore, there were differences in the identity and time of peptides release. The knowledge of the kinetics of peptide formation could have important implications in their possible bioactivity and allergenic response.

The control of lipid digestion is crucial in the development of products for weight management strategies. The delay of lipid digestion might allow the presence of undigested lipid in the distal intestine (ileum), which may increase the feelings of satiety (*i.e.* ileal brake). The behaviour of the lipid kinetics during digestion was investigated in an encapsulated oil-in-water emulsion in alginate beads when incorporated in a yoghurt matrix.¹²⁸ This was performed using the DIDGI® system but adding a third compartment to mimic the second part of the small intestine (jejunum + ileum). The encapsulation of the emulsion delayed lipolysis by 3 hours when compared to the free emulsion. This showed that the DIDGI® system could be used for assessing differences in lipid digestion kinetics and was adapted to be representative of the different sections of the small intestine, so far applied to liquid foods. The DIDGI® was also used to gain more information about the glycaemic response by studying the digestion kinetics of starch and the contribution of the salivary and pancreatic α -amylases.¹²⁹ This was assessed in wheat-based and gluten-free pasta, and white bread. The importance of the use of salivary α -amylase was highlighted in the study since some studies have skipped oral digestion due to its shortness. Furthermore, salivary α -amylase remains active in the stomach until it is inactivated at pH between 3.0 and 3.8, highlighting the importance of using more physiological digestion models to investigate carbohydrate digestion.





The main limitations of the DIDGI® are that the vertical orientation of the main body and antrum does not mimic the gastric anatomy. The mixing in the compartments consists only in a basic stirring using a propeller, which is not physiologically relevant, and the gastric physical contractions are not simulated.

The established examples given above were selected since they are the most representative and are widely cited in the literature. However, other more recent but less validated dynamic models have been published in recent years that are working towards the development of more realistic GI digestion simulation. For instance, the *in vitro* mechanical gastric system (IMGS),¹³⁰ the new dynamic *in vitro* human stomach system (DIVHS),¹³¹ the gastric simulation model (GSM)¹³² and the artificial gastric digestive system (AGDS).⁶⁶ Their general features are described in Table 5 for comparison. All these models incorporate the J-shaped gastric morphology and anatomical structures with the aid of 3-D printing technology although the biochemical aspects of the model may be rather more primitive. The AGDS exhibited a similar digestion behaviour of the α -lactalbumin protein solution to the *in vivo* data.⁶⁶ The DIVHS was able to generate consistent gastric emptying profiles of both solid and liquid fractions in the mixed meal of beef stew and orange juice with that reported *in vivo*. Furthermore, this model showed qualitative correlations regarding gastric pH, particle size distribution and emptying profiles of cooked rice with the *in vivo* data from the literature.

As general conclusion, the dynamic models can be useful to gain insights into food digestion and establish mechanistic relationships with physiological responses related to specific



Table 5 Examples of more recent and less validated dynamic models simulating the gastric phase

System	Photo	Gastric dynamics	Main body	Control units	T control	Mixing mechanism	Ref.
<i>In vitro</i> mechanical gastric system (IMGS)		<ul style="list-style-type: none"> - pH control ✓ - Digestive fluids secretion X - Gastric emptying X - Mixing and shear stresses ✓ 	J-shape; latex; 900 mL	pH stat automatic titration unit	37 °C; water	Adjusting acrylic pistons acting in pairs, each piston is driven by a motor with different torques	Barros <i>et al.</i> (2016) ¹³⁰
Gastric simulation model (GSM)		<ul style="list-style-type: none"> - pH control X - Digestive fluids secretion ✓ - Gastric emptying ✓ - Distribution, amplitude and frequency of contractions ✓ 	J-shape; latex; 600 mL	Peristaltic pumps	37 °C; light bulbs and fan	A series of syringes that work independently with gas	Li <i>et al.</i> (2019) ¹³²
Dynamic <i>in vitro</i> human stomach system (DIVHS)		<ul style="list-style-type: none"> - pH control X - Digestive fluids secretion ✓ - Gastric emptying ✓ - Peristaltic contractions ✓ 	J-shape with folds/wrinkles inside, silicone, 400 mL	Peristaltic pumps	37 °C, lamp	Electromechanical instrument composed of a series of motors, rollers and eccentric wheels	Wang <i>et al.</i> (2019) ¹³¹
Artificial gastric digestive system (AGDS)		<ul style="list-style-type: none"> - pH control ✓ - Digestive fluids secretion ✓ - Gastric emptying ✓ - Peristaltic contractions ✓ 	J-shape; silicone; 1700 mL	pH stat automatic titration unit; peristaltic pumps	37 °C, lamp	Two sets of symmetrical rollers and one set of contrary movement of the roller	Liu <i>et al.</i> (2019) ⁶⁶



food consumption. The dynamic models have been used to study nutrient breakdown, structural changes and release of food components showing the kinetics of digestion. However, they have mostly provided a partial view of the fate of food digestion focused on the aim of the study. The system can be very useful for the simulation of specific populations such as the infant or the elderly. However, the specific conditions of digestion need to be standardised for systematic use. In general, these dynamic models need further validation with *in vivo* parameters in light of the new advanced techniques for studying *in vivo* digestion. These systems vary in the biochemical composition of the digestive solutions used in each phase, for example the type and enzyme concentrations, the electrolytes and buffers, between the dynamic models as well as in the studies using the same system. There is also no consensus agreement on how these models reproduce the relevant motility of the stomach. In addition, the shape of stomach in most of the dynamic models is not representative of the actual morphological and anatomical features.

The use of dynamic systems is technically very complex and costly, compared to the static model. It is time-consuming due to the long preliminary preparations enabling the performance of, usually, one digestion per day. Furthermore, the data provided by these models are usually more difficult to interpret. They do not include any feature related to feedback hormonal mechanisms, resident microbiota or immune system. In addition, products of digestion are not progressively removed from the compartments, except in the case of TIM, and they do not provide the simulation of further hydrolysis by the brush border enzymes. Therefore, there are still opportunities for further improvements in dynamic *in vitro* models.

2.5 Digestion models relevant to absorption

After luminal GI digestion, there is a last step of further degradation of hydrolysis products from dietary lipids, proteins and carbohydrates by brush border membrane (BBM) enzymes at the level of small intestinal epithelium before absorption. The term brush border is often used to refer to the microvilli and glycocalyx, on the apical side of the enterocytes lining the small intestinal surface. More than twenty different BBM-associated enzymes have been identified,^{147,148} among which peptidases (exopeptidases, endopeptidases, enteropeptidases and dipeptidases) and di(oligo)saccharidases are most abundant. Thus, this section aims to focus on the action of BBM peptidases and to a lesser extent BBM carbohydrases.

Exopeptidases progressively erode amino acids generated by gastric and pancreatic proteases, whereas endopeptidases can hydrolyse larger polypeptides. However, the hydrolysis of high molecular weight polypeptides is very slow compared to the hydrolysis of short peptides with less than 20 residues.¹⁴⁹ A significant amount of BBM enzymes are also present in the intestinal lumen, because of the rapid turnover and shedding of epithelial cells.¹⁵⁰ The distribution of BBM enzymes is not homogeneous along the small intestine. In general, the activity increases longitudinally from the proximal duodenum to the distal ileum, as the bulk of the chyme also decreases. Thus,

the optimum BBM digestion/absorption of gastro-pancreatic generated peptides takes place in the distal duodenum and proximal jejunum.¹⁵¹ To date, there are no standard protocols to approach this final step of digestion.¹⁵¹ The lack of consensus regarding incubation conditions (pH, media composition, times, enzyme to substrate ratio, *etc.*), along with the limited availability of BBM enzymes are the main reasons why this step is omitted in most of *in vitro* digestion models. In turn, the standardisation requires data about the activity of BBM enzymes, which are still incomplete, and adequate validation of the use of BBM enzymes. The characterisation of BBM material is complex due to the presence of active intracellular components and variability in enzyme activity because of the different expression among the different segments of the small intestine as well as the type of diet, host genetics, age, *etc.* In addition, it is not yet clear whether the final degradation by BBM enzymes is sufficiently significant to be physiologically relevant, and/or the dependence on the substrate. One of the simplified methods is the use of isolated BBM vesicles, although it may lack sufficient physiological relevance, while more complex procedures using tissue or model organ are not widely applicable and not sufficiently established.¹⁵⁰ Regarding the use of BBM vesicles, studies have mostly used BBM enzymes isolated from the jejunum of pig, rat and cow, when access to human source is restricted.^{152,153} This is because major peptidases have been found structurally and functionally homologous in these animal species and human.¹⁵⁰ Nevertheless, the porcine source is a better substitute for human BBM enzymes due to the relatively high stability and yield, and well-correlated physiology of the small intestine, in both anatomical and dietary terms.^{154,155} One of the most broadly used procedures to isolate BBM vesicles is from Shirazi-Beechey *et al.*¹⁵⁶ For protein digestion, the use of a last step of *in vitro* intestinal digestion with BBM peptidases supported the discovery of wheat prolamin derived peptides that elicit celiac disease *in vivo*.¹⁵² Picariello and co-workers showed that BBM enzymes significantly increased the degree of hydrolysis of milk proteins from 55–60% after GI digestion up to 70–77% after BBM hydrolysis.¹⁵³ If properly validated *in vivo*, these results might question the role of putative bioactive peptides supplied by an average daily intake of milk, which would be present at too low concentrations for exerting any local or systemic activity. A recent study showed that this step only affected short peptides (<20 residues) and was not relevant for the study of allergenicity of native and aggregated egg ovalbumin since shorter peptides may have lost already the antigenic properties by pancreatic proteases.¹⁵⁷ In contrast, Di Stasio and co-workers found that BBM digestion after oral-gastro-duodenal digestion reduced the allergenicity of roasted peanuts compared to raw peanuts, or compared to raw/roasted peanuts after only oral-gastro-duodenal digestion.¹⁵⁸ This suggests that BBM peptidases contributed to further hydrolyse the shorter peptides generated from digestion of roasted peanuts destroying specific domains of peanut allergens. Similarly, Gianfrani and co-workers found that *in vitro* gastro-pancreatic digesta of gliadin from einkorn (a diploid ancestor



of wheat) have comparable immunogenic potential to that of common wheat when assayed against specific intestinal T-cell lines from celiac disease patients, but this immunotoxicity of einkorn is considerably reduced after BBM digestion when compared to wheat.¹⁵⁹ They found that BBM digestion dramatically affected the stability of einkorn resistant peptides, retaining a lower number of minor T-cell stimulatory epitopes. These results support *in vivo* evidence of the lower-toxicity of certain wheat species for the celiac disease patients and the correspondence of the digestome. Therefore, the use of BBM enzymes has to be reviewed case by case. In these studies, the incubation conditions of BBM peptidase activity to substrate ratio was 100 mU/100 mg peptides, the incubation times were 4–6 hours, and the incubation pH was in the range of 7–8, based on previous procedures demonstrating certain *in vitro*–*in vivo* consistency.^{152,160} Nevertheless, these conditions were rather empirical. The BBM enzymes activity is critical and even if accurately evaluated individually or in total, the challenge remains in calculating the amount of chyme encountering the intestinal mucosa.¹⁵⁰ Therefore, the parameter of BBM enzymes to substrate ratio has yet to be fairly extrapolated for *in vitro* purposes.

For carbohydrate digestion, Ferreira-Lazarte and co-workers studied the GI digestion of reconstituted skim milk powder with incorporated prebiotic oligosaccharides and reported some differences between the *in vitro* protocols applied, gastro-intestinal Infogest *versus* gastric Infogest complemented with intestinal phase using rat small intestinal extract.⁸⁰ The authors attributed the different results to the presence of lactase (a BBM enzyme) in the small intestinal extract from rat, which would represent a more physiologically relevant scenario for carbohydrate digestion. Recent advances on the *in vitro* digestion of carbohydrates are addressing the use of mammal or recombinant mucosal carbohydrases and have been reviewed elsewhere.^{161,162}

BBM digestion can be coupled with absorption studies since the uptake is the ultimate barrier between an active compound and the systemic circulation. Regarding *in vitro* models of absorption, these span from simple membrane systems to cell model systems, and more complex *ex vivo* models include intestinal tissues, although the viability time *ex vivo* is a limitation if shorter than the typical intestinal transit time. In all these techniques, sampling and composition analysis of the collected aliquots are required to measure the release/transport of the bioactive compound of interest. At least eight of the main BBM peptidases have been identified at the cell surface of Caco-2 cells.¹⁶³ However, the digestion patterns generated by the BBM vesicles are appreciably different from those obtained by Caco-2 cell monolayer.¹⁶⁴ This may be related to the heterogeneous and dissimilar distribution of Caco-2 peptidases from the enterocyte peptidases.¹⁶⁵ Investigations are still needed to define physiologically relevant operative parameters.

The simplest *in vitro* membrane systems to study the transport of nutrients or bioactive compounds across the intestinal epithelium are dialysis bags or tubing containing the digesta and suspended in simulated intestinal fluids for a more accu-

rate approach¹⁶⁶ or dialysis membrane implemented in more sophisticated *in vitro* dynamic digestion models, such as TIM-1.¹⁶⁷ Nevertheless, this approach does not mimic the epithelial cell behaviour and bioaccessibility is rather the measuring parameter than bioavailability. A more realistic model of the human intestinal epithelium is achieved with Caco-2 monolayer cell cultures¹⁶⁸ or co-cultures of Caco-2. These can be grown either in a single cell culture plate well for uptake studies or in a membrane insert in a Transwell® system for transport studies.¹⁶⁹ Caco-2 monolayer only reproduces enterocytes and therefore exhibit microvilli and the expression of enzymes and transporters.¹⁷⁰ Co-cultures of Caco-2 and other cell lines are alternatively used to better reproduce aspects of the multicellular intestinal epithelium by including M cells (Caco-2 and RajiB or lymphocyte co-culture) and mucus secreting Goblet cells (Caco-2 and HT29-MTX co-culture). Good descriptions of the methods for these types of cell cultures are given elsewhere.¹⁷¹ The integrity of the cell monolayer is usually evaluated by measuring the transepithelial electrical resistance (TEER). Ideally, coupling *in vitro* digestion models with human cell cultures would provide a more realistic scenario of absorption than using cell culture on undigested/pure systems. These tandem studies can use simple static *in vitro* digestion, including the Infogest harmonized protocol, or dynamic models (*e.g.* TIM) prior to cellular uptake and account for the effect of the food matrix and digestive media.^{120,172,173} For instance, Deat *et al.* combined the TIM dynamic model of GI digestion of whole food with cultures of Caco-2 cells to determine the bioavailability of phytochemicals.¹²⁰ Their *in vitro* results, namely lower bioavailability of lycopene compared to α -tocopherol, were consistent with *in vivo* data from literature. Vors and co-workers coupled static *in vitro* GI lipolysis of emulsions with Caco-2 cells to study lipid absorption and metabolism.¹⁷² The authors showed that the emulsion composition influenced the activation of lipid metabolism and triglyceride secretion by Caco-2 cells. Felice *et al.* coupled the Infogest digestion protocol with Caco-2 cell model to study the bioavailability of magnesium from marine-derived multimineral supplement and compared with other sources of magnesium.¹⁷³ The marine-derived product had comparable magnesium *in vitro* bioavailability to the source with reported higher *in vivo* bioavailability. To maintain the barrier integrity of the Caco-2 cell monolayers in these experiments, digested samples may require previous ultracentrifugation, filtration and dilution before adding to the cell cultures or, alternatively, filtering the enzyme and buffer solutions before *in vitro* GI digestion and diluting digested samples afterwards, in order to minimise bacterial contamination and avoid toxicity.

A step further on cell model systems has been achieved with the biomimetic microfluidic device gut-on-a-chip. This consists of two hollow microchannels separated by a porous flexible membrane coated with extracellular matrix and lined by human intestinal cells, *e.g.* Caco-2.¹⁷⁴ Fluid flow and mechanical stress are applied *via* vacuum microchambers alongside the microchannels, which mimic the intestinal peri-



stalsis and increase the paracellular transport without compromising the integrity of the cell monolayer. In addition, human gut isolated microflora can be cultured on the luminal surface of the Caco-2 monolayer to account for the presence of living microorganisms.

Ex vivo absorption in segments of animal or human gut offers a better representation of the morphological and physiological features of the intestinal wall, such as the presence of all the relevant cell types and architecture, and the presence of a mucus layer allowing the simulation of the possible further hydrolysis by BBM enzymes.¹⁷⁵ These tissue segments can be used to follow the transport of nutrients or bioactive compounds across the intestinal epithelium, permeability, absorption or interactions with the mucus layer.¹⁷⁶ The main limitation is that the tissue is only viable for 1 to 3 hours depending on whether the muscle layers are present or removed. The simpler techniques are intestinal rings or segments, which are immersed into highly oxygenated buffer containing the compound of interest. The main disadvantage in this procedure is that there is no isolation of the luminal (apical) side from the serosal (basolateral) side, thus mainly the accumulation of nutrients or bioactive compounds into the enterocytes is determined rather than transport.¹⁷⁷ The separation of apical and basolateral compartments can be achieved with the everted sac model, whereby a segment of intestine can be sutured at one end, the digesta or compound under study introduced and the open end also sutured and immersed in physiological solution, such as Ringer.¹⁷⁸ Another alternative is opening the intestinal segment by cutting longitudinally so that the tissue can be mounted in an Ussing chamber. Here, the tissue is pinned to a frame dividing two semi-chambers, one facing the apical side, where the system of interest is loaded, and the other facing the basolateral side, where the appearance of the loaded system is monitored.^{179,180} The electrophysiological properties: TEER of the tissue, potential difference between the two chambers and short-circuit current of the tissue are monitored throughout the experiment as indicators of tissue integrity and viability. Relatively high TEER values reflect the activity of the ion pumps on the epithelial membrane, which is characteristic of viable tissue. The permeability of hydrophilic markers is often monitored as well to follow tissue integrity, where a low permeability is associated with intact tissue.¹⁸¹ Most of these intestinal tissue models make use of an animal source, rats, rabbits and pigs being the more common, due to the limited availability of healthy human intestinal tissue.¹⁸² Although pigs share more physiological and immunological similarities to human than rodents, the extrapolation of data to humans is complicated due to interspecies differences.¹⁸³ Even the large inter-individual variability in humans make the interpretation of the results difficult in small studies. As for cell models, tandem *in vitro* digestion with Ussing chambers studies have been reported in the literature. In these studies, the digested samples only require dilution before being in contact with intestinal tissues. García *et al.* used the digesta of commercial fish products (obtained with the static Infogest harmonized protocol) in the

apical side of Ussing chambers to determine the *ex vivo* bioavailability of antioxidants.¹⁸⁴ They found faster rates of transport for the products counterpart enriched with protein hydrolysates from sea cucumber. Mackie and co-workers coupled the static *in vitro* digestion (Infogest) of emulsions stabilised by cellulose nanocrystals (CNC) with Ussing chambers technique and compared the GI stability and lipid transport across murine intestinal epithelium with that of conventional protein-stabilised emulsions.¹⁸⁵ It was shown that CNC clusters post-digestion were entrapped in the mucosa layer probably limiting the bile and lipid transport, in particular of saturated free fatty acids, in comparison with protein emulsion. These findings have important implications in the modulation of lipid absorption and bile recycling in the context of cholesterol-lowering potential ascribed to dietary fibre. In a more recent study, Mulet-Cabero and co-workers coupled an *in vitro* semi-dynamic gastric digestion with *in situ* static intestinal digestion in the apical side of the Ussing chamber to study absorption of amino acids from dairy formulations.⁶⁷ This approach is even more realistic since intestinal digestion and absorption are simultaneous processes. More importantly, a positive correlation was found between gastric emptying, GI bioaccessibility and absorption within the context of “fast” and “slow” proteins.

The limitations of using freshly excised intestinal tissues for transport studies are on one hand associated with the removal of the serosa and *muscularis* layers. The lack of circulation and lymphatic drainage leads to water accumulation and tissue swelling. This is overcome to some extent by reducing the osmotic gradient between the apical and basolateral side (when individualised as in Ussing chambers). To this end, glucose is normally substituted with mannitol in the apical compartment.¹⁸¹ Still the lack of circulation can hinder the passage of especially larger molecules through the subepithelial layer and it is thus possible that the subepithelium presents more of a barrier in *ex vivo* experiments than it does *in vivo*. Furthermore, toxicological responses dependent on the systemic immune system cannot be studied and the lack of innervation and the subepithelial muscle layer means that responses dependent on nerve signalling and peristaltic movements, respectively, will not be captured *ex vivo*.¹⁸² Additionally, the reduced area of the intestinal tissue may result in saturation in the tissue hampering the transport. Overall, the technical challenge of these systems, limits the throughput, nonetheless good *in vitro*–*in vivo* correlation has been shown for small molecules, such as drug and peptides.^{186–188} Promising *ex vivo*–*in vivo* correlation in nanoparticle uptake in human intestinal tissue has also been reviewed.¹⁸²

2.6 *In silico* models of digestion

In general, the complex nature of the problem and the limited amount of reliable data to base models on has meant that only a limited amount of *in silico* models have been used. Although in many ways one might consider the oral cavity a difficult compartment to model, Harrison *et al.* were able to model the



fracture of agar gels.¹⁸⁹ They were able to show that gel fragment size results were mildly sensitive on the initial position of the agar samples relative to the position of the jaw and highly sensitive to the measure of fracture toughness. In other words, foods break according to the properties of the food not their location in the mouth.

Most of the research into *in silico* models of digestion has come from the pharmaceutical arena.^{190,191} For example, in their review, Fois *et al.* discussed a number of computational fluid dynamics (CFD) approaches that have been used to understand mass transfer in the GI tract. Although there is no absorption of nutrients during the gastric phase, the extent of mixing and shearing has a significant impact of breakdown and emptying of solid and semi-solid meals. Additionally, the change in pH and the presence of food in relation to drug delivery is now coming under more scrutiny.¹⁹¹ The difficulty of assessing these physical processing parameters *in vivo* has led to a heavy reliance on data from modelling in understanding gastric shear fields.¹⁹² These simulations highlight the very limited mixing in the gastric compartment under post-prandial conditions relating to the consumption of a meal where the chyme will have significant rheological properties. More recently, Harrison *et al.* used a coupled biomechanical smoothed particle hydrodynamics model to show that the rate of gastric emptying increased with a high frequency of contractile waves and had a nonlinear relationship with content viscosity.¹⁹³ Increased resistance to flow into the duodenum was also shown to reduce the rate of emptying. The degree of gastric mixing was found to be insensitive to changes in the frequency of contractile waves for fluid with a viscosity of water but to be substantially affected by the viscosity of the gastric content and this confirms the findings of Drechsler and co-workers.¹⁹²

In addition to gastric processing, mixing in the small intestine has also been simulated by a number of researchers. These include the work by Moxon *et al.* on luminal mixing¹⁹⁴ and Lentle and co-workers on intestinal mixing and flow around villi.¹⁹⁵ The CFD simulations suggest that there is ongoing augmentation of luminal mixing at the periphery of the lumen to promote flow around and between adjacent villi. Thus making mixing and absorption of nutrients and bioactives more efficient. The final part of the intestine is the colon and Sinnott *et al.* have modelled colonic motility with regard to the transport of fluid.¹⁹⁶ They were able to show that in the absence of descending inhibition (DI), poor transport properties and high intra-luminal pressures were observed. The importance of DI as a physical mechanism for peristalsis appeared to be that it enabled excellent compact transport with reduced muscular work. It is clear that luminal composition has an important effect on mixing and thus transport and absorption at all stages of digestion.

More recently, improvements in data and modelling tools have led to ideas about their use for improving the bioaccessibility of lipophilic nutrients¹⁹⁷ and more realistically predicting protein hydrolysis.¹⁹⁸ In the latter article a combination of *in vivo* and *in silico* methods were used to predict bioactive

peptide release from meat. This mixed type approach has also been used to predict appetite responses to foods based on gastric rheology combined with amino acid and glucose absorption.¹⁹⁹ The researchers used an artificial neural network approach with a number of training sets to build the predictive capacity and link the *in vitro* measures to human participant visual analogue scale scores for fullness and hunger. Although this area of modelling is still in its infancy, it is clear that developments in CFD and artificial intelligence approaches have the potential to make *in silico* models powerful predictive tools with the ability to predict physiological responses to foods.

3 *In vivo*–*in vitro* comparisons

In vitro models aim to mimic the situation *in vivo* although some models simulate the physiological conditions more closely than others do. These models aim to provide data that can predict human digestion but there is the need to understand their limits and accuracy. This should be performed by direct *in vivo*–*in vitro* comparison using the same food samples including raw material and processing. These studies are limited due to constrictions of *in vivo* studies and the challenge of how to compare *in vitro* bioaccessibility data with *in vivo* bioavailability data. Table 6 shows examples of this *in vivo*–*in vitro* correlation studies illustrating the relevance and some of them are discussed in this section.

3.1 *In vivo*–*in vitro* correlation in protein research

In vivo studies have been usually applied to assess the nutritional quality of food proteins. This is most frequently evaluated by the protein digestibility-corrected amino acid score (PDCAAS) or digestible indispensable amino acid score (DIAAS).²⁰⁰ DIAAS is based on the true ileal digestibility of each indispensable AA. The true ileal digestibility should preferably be determined *in vivo* by, for instance, sampling *via* a naso-ileal tube after intake of ¹⁵N-labeled AAs. These scores are based on the overall ability of humans to digest proteins, which does not include the rate of digestion. However, the postprandial profile by which AAs are present in the blood (*i.e.* aminoacidemia) is of great relevance and can exert different physiological effects. This is a similar concept of glycemia in relation to starch digestion but it has not been studied in that depth. For instance, a rapid presence of AAs, especially essential AAs such as leucine, was observed to enhance muscle protein synthesis response in the elderly,²⁰¹ which could help in the problem of sarcopenia.

Some studies have aimed to compare the protein digestion between animal and dynamic *in vitro* models by analysing the digesta after gastric or gastrointestinal digestion. For instance, Egger and co-workers compared the digestion of skim milk powder using the data of protein hydrolysis by gel electrophoresis and peptide patterns obtained by a pig model and the dynamic DIDGI® system.¹⁵ The authors observed the formation of a firm coagulum in the pig stomach whereas the



Table 6 Examples of *in vivo*–*in vitro* correlation studies

<i>In vivo</i> model	<i>In vitro</i> model	Food substrate tested	Parameters assessed	Physiological relevance	Ref.
Pig ($n = 8$)	Static	Skim milk powder	Protein hydrolysis (qualitatively) and, peptide and AA analysis during GI digestion <i>In vivo</i> : sample at 1.5 h of gastric/intestinal and at 3 and 6 h of intestinal digestion <i>In vitro</i> : during gastric phase (2 h) and intestinal phase (2 h) <i>In vitro</i> and <i>in vivo</i> : kinetics of residual immunoreactivity of β -lactoglobulin and caseins during gastric (210 min) and intestinal (210 min) digestion Protein hydrolysis (qualitatively) and, peptide and AA analysis during GI digestion <i>In vivo</i> : sample at 1.5 h of gastric/intestinal and at 3 and 6 h of intestinal digestion <i>In vitro</i> : during gastric phase (1.5 h) and intestinal phase (3 h)	- The two <i>in vitro</i> endpoints (gastric and intestinal phase) reflected the <i>in vivo</i> situation of protein bioaccessibility - Peptide correlation of 0.8 and 0.6 of overall proteins in the endpoints of gastric and intestinal, respectively. - Different gastric behaviour	Egger <i>et al.</i> (2019) ¹⁵
Piglet ($n = 18$)	Dynamic model, DIDGI®	Infant milk formula	<i>In vitro</i> and <i>in vivo</i> : kinetics of residual immunoreactivity of β -lactoglobulin and caseins during gastric (210 min) and intestinal (210 min) digestion Protein hydrolysis (qualitatively) and, peptide and AA analysis during GI digestion	The residual concentrations of caseins and β -lactoglobulin in gastric and intestinal digesta were statistically not different ($p < 0.05$)	Menard <i>et al.</i> (2014) ¹²⁴
Pig ($n = 8$)	Dynamic model, DIDGI®	Skim milk powder	<i>In vitro</i> and <i>in vivo</i> : kinetics of residual immunoreactivity of β -lactoglobulin and caseins during gastric (210 min) and intestinal (210 min) digestion Protein hydrolysis (qualitatively) and, peptide and AA analysis during GI digestion <i>In vivo</i> : sample at 1.5 h of gastric/intestinal and at 3 and 6 h of intestinal digestion <i>In vitro</i> : during gastric phase (1.5 h) and intestinal phase (3 h)	- Peptide correlation of 0.85 and \sim 0.5 of overall proteins in the endpoints of gastric and intestinal, respectively. - Formation of gastric solid coagula but different consistency	Egger <i>et al.</i> (2019) ¹⁵
Calf	Semi-dynamic model	Bovine whole milk	Non-protein, and protein nitrogen, AA analysis, estimation of caseins/ whey proteins during gastric digestion <i>In vivo</i> : monitoring for 6 h <i>In vitro</i> : monitoring for 3 h <i>In vivo</i> : blood triglycerides rate <i>In vitro</i> : FFA release during intestinal digestion after gastric step, microstructure, particle size emulsion <i>In vivo</i> : blood triglycerides rate for 6 h <i>In vitro</i> : FFA release during intestinal digestion (3 h) after static gastric step (2 h), microstructure and particle size emulsion	The <i>in vitro</i> kinetics of protein patterns generally agrees with <i>in vivo</i> data, applying <i>in vitro</i> time/2	Yvon <i>et al.</i> (1992) ²⁰³
Human ($n = 8$)	Static	Oil-in-water emulsion using phospholipids, sodium stearoyl lactylate liquid oil and liquid oil/solid fat	<i>In vitro</i> : FFA release during intestinal digestion after gastric step, microstructure, particle size emulsion <i>In vivo</i> : blood triglycerides rate for 6 h <i>In vitro</i> : FFA release during intestinal digestion (3 h) after static gastric step (2 h), microstructure and particle size emulsion	Partial correlation rates of FFA (<i>in vitro</i> intestinal phase) and triglyceride concentration in plasma	Golding <i>et al.</i> (2011) ²⁰⁵
Human ($n = 8$)	Static	Phospholipid stabilised emulsion, sodium caseinate + monoglyceride emulsion, sodium caseinate + monoglyceride emulsion in gelatine gel and sodium caseinate + monoglyceride emulsion in starch dispersion	<i>In vitro</i> : blood triglycerides rate for 6 h <i>In vitro</i> : FFA release during intestinal digestion (3 h) after static gastric step (2 h), microstructure and particle size emulsion	Partial correlation rates of FFA (<i>in vitro</i> intestinal phase) and triglyceride concentration in plasma	Wooster <i>et al.</i> (2014) ²²³
Human ($n = 12$)	Semi-dynamic model	Whey protein (leucine-enriched) and calcium casein protein at two different concentrations containing carbohydrates and fat	<i>In vivo</i> : AAs analysis, glucose and insulin concentrations in blood samples for 4 h <i>In vitro</i> : protein digestion rate and, peptide and AAs analysis during intestinal digestion (90 min) after gastric phase (90 min) <i>In vivo</i> : gastric structuring, satiety assessment and CCK determination for \sim 3 h	The samples presented similar variation of essential AAs after intestinal digestion	Luiking <i>et al.</i> (2016) ⁸¹
Human ($n = 10$)	Semi-dynamic model	Semi-solid sample (cheese and yoghurt) and liquid sample (oil-in-water emulsion stabilised by milk proteins)	<i>In vitro</i> : gastric structuring, satiety assessment and CCK determination for \sim 3 h <i>In vitro</i> : gastric structuring and, protein and lipid digestibility during intestinal digestion (1 h) after gastric digestion (\sim 3 h) <i>In vivo</i> : glucose concentration in blood samples for 2 h <i>In vitro</i> : glucose, maltose and oligosaccharides concentration at 1 and 5 h	- Correlation in gastric behaviour	Mulet-Cabero <i>et al.</i> (2017) ⁷⁴
Human ($n = 5$ – 10)	Static	Cooked and sweet potatoes, white and brown rice, white and wholemeal spaghetti, buckwheat, millet, oats, kidney beans, soya beans, lentils and marrowfat pea.	<i>In vitro</i> : glucose, maltose and oligosaccharides concentration at 1 and 5 h	- The higher levels of proteins and lipids released from semi-solid sample <i>in vitro</i> can correlate with its higher satiety Positive correlation between the concentration of carbohydrate liberated <i>in vitro</i> and the glycaemic index at 1 h ($r = 0.8627$) and 5 h ($r = 0.8618$)	Mackie <i>et al.</i> (2013) ²⁰⁷ Jenkins <i>et al.</i> (1982) ²²⁴



Table 6 (Contd.)

<i>In vivo</i> model	<i>In vitro</i> model	Food substrate tested	Parameters assessed	Physiological relevance	Ref.
Human (<i>n</i> = 8)	Static	Corn flakes, white bread, cooked white spaghetti, and cooked pearled barley	<i>In vivo</i> : glucose concentration in blood for 2 h <i>In vitro</i> : glucose concentration during intestinal digestion at 20 and 120 min	Correlation between the mean glycaemic response values for all the subjects and the rapid available glucose content of the test meals (20 min) ($r = 0.981$)	Englyst <i>et al.</i> (1999) ²¹¹
Human (<i>n</i> = 30)	Static	Cereals: white bread, spaghetti, rice and biscuits. Legumes: lentils, chick-peas and beans. Vegetables: peas, boiled potatoes and crisp potatoes	<i>In vivo</i> : glucose concentration in blood for 3 h <i>In vitro</i> : glucose concentration during intestinal digestion for 3 h	Correlation between the starch hydrolysis (%) and glycaemic index: $r = 0.837$ (30 min), $r = 0.883$ (60 min), $r = 0.909$ (90 min), $r = 0.890$ (120 min) and $r = 0.888$ (180 min)	Gohi <i>et al.</i> (1997) ²¹²
Human (<i>n</i> = 18)	Static	Muffins and breads	<i>In vivo</i> : blood glucose concentration for 3 h <i>In vitro</i> : reducing sugar concentration during intestinal digestion (3 h) after gastric digestion (1 h)	<i>In vitro</i> method overestimated <i>in vivo</i> method, the trend in the reduction in glycaemic index seemed to be similar in both methods	Ferrer-Mairal <i>et al.</i> (2012) ²²⁵
Human (<i>n</i> = 9)	Static	Two wheat porridge meals: coarse (2 mm particles) and smooth (<0.2 mm particles)	<i>In vivo</i> : blood glucose, insulin, C-peptide, lipids, and gut hormones concentrations for 4 h <i>In vitro</i> : hydrolysis index (quantification of maltose) for 1.5 h	Same differences in the extent of hydrolysis and bioavailability of glucose between the samples	Edwards <i>et al.</i> (2015) ²²⁶
Human (<i>n</i> = 12)	Dynamic model, DGM	Barley flakes (micronized and extruded)	<i>In vivo</i> : glucose concentration in blood for 2 h <i>In vitro</i> : microstructure, gastric viscosity and glucose concentration during intestinal digestion (1 h) after gastric phase (30 min)	Similar range in the glycaemic index	Ballance <i>et al.</i> (2013) ⁹³
Human (<i>n</i> = 13)	Dynamic model, TIM	Barley and oat Tempe	<i>In vivo</i> : glucose concentration in blood for 2 h <i>In vitro</i> : quantification maltose formation, microstructure during intestinal digestion for 3 h	Similar range in the AUC values	Alminger <i>et al.</i> (2012) ¹³³ Alminger <i>et al.</i> (2008) ²¹⁵
Human (<i>n</i> = 10)	Static	Meal containing α - and γ -tocopherol, β -carotene, lycopene, and lutein bioaccessibility from their main dietary sources	<i>In vivo</i> : all <i>trans</i> and <i>cis</i> -carotenoids content from stomach (for 3 h) and duodenal digesta (for 3 h) <i>In vitro</i> : carotenoids and vitamin E (micellar phase) in endpoint of digestion (gastric phase for 3 h and intestinal phase for 2 h)	Bioaccessibility values measured with the <i>in vitro</i> model were in the same range than those measured <i>in vivo</i> ($r = 0.90$) The spinach lutein bioaccessibility was about 5-fold higher <i>in vitro</i> than <i>in vivo</i>	Reboul <i>et al.</i> (2006) ²¹⁸ Tyssandier <i>et al.</i> (2003) ²¹⁹
Human (<i>n</i> = 72)	Static	A high-polyphenol diet, the main dietary sources were artichokes, fennel, onion, spinach, arugula salad (rucola), orange, dark chocolate bar, decaffeinated coffee and green tea	<i>In vitro</i> : phenolic metabolites (for hydroxylated phenylpropionic and phenylacetic acids, some benzoic acid derivatives and mammalian lignans) in 24 h urine samples <i>In vitro</i> : phenolic metabolites formation after 6 h incubation	Low correlation ($r = 0.280$) found for 15 metabolites	Vetrani <i>et al.</i> (2016) ²²⁰
Human (<i>n</i> = 15)	Static	Tortillas fortified with various form of iron (native iron, ferrous fumarate, ferrous bis-glycinate, FeNa EDTA)	<i>In vivo</i> : iron status and bioavailability in blood samples on day 15 and 29 <i>In vitro</i> : dialyzable iron after GI digestion weeks <i>In vitro</i> : folate concentration in blood for 4 weeks <i>In vitro</i> : folate concentration after GI digestion and absorption	The iron solubility <i>in vitro</i> and the bioavailability <i>in vivo</i> were highly correlated ($r = 0.89$) <i>In vitro/in silico</i> approach can predict <i>in vivo</i> folate concentrations in blood	Walter <i>et al.</i> (2003) ²²⁷
Human (<i>n</i> = 69)	Dynamic model, TIM-1	Folic acid fortified milk (ultra-high temperature sterilised and pasteurised)	<i>In vivo</i> : folic acid concentration in blood for 4 weeks <i>In vitro</i> : folic acid concentration after GI digestion and absorption		de Jong <i>et al.</i> (2005) ²²⁸ Verwei <i>et al.</i> (2006) ²²¹

AA: amino acid, FFA: free fatty acid, GI: gastrointestinal, AUC: area under the curve.



coagulation in the *in vitro* model was much less compact. The kinetics of protein hydrolysis were difficult to compare since there was no time-following during *in vivo* digestion, just one sample from the stomach and three points in different parts of the intestine were collected. Peptide identifications were performed for the five most abundant milk proteins (β -casein, β -lactoglobulin, α_{s1} -casein, α_{s2} -casein, and κ -casein). The peptide patterns of the gastric and intestinal endpoints were compared to those from the pig *in vivo*.²⁰² The total correlation calculated over all proteins was 0.85 and ~ 0.5 in the endpoints of the gastric and intestinal digestion, respectively. This lower outcome in the intestinal compartment, in particular, in the ileum, could be due to absorption processes are not mimicked in the *in vitro* model. Similar results were obtained when the same *in vivo* protocol was compared to a static digestion using standardised Infogest conditions.²⁰² In contrast, Yvon and co-workers obtained a good agreement in protein digestion data of gastric emptying obtained using a calf and semi-dynamic models.²⁰³

Luiking and co-workers determined in humans the AA concentration in plasma after the consumption of different concentrations of calcium caseinate and whey proteins solutions.⁸¹ In the first 90 min, there was a rapid and higher increase in the whey protein samples compared to the caseinate samples. However, *in vitro* the initial intestinal protein digestion rate of casein supplements was higher than that of whey protein supplements. Nevertheless, the overall cumulative release of AAs over 90 min was higher for whey protein samples as observed *in vivo*. The semi-dynamic model used provided the kinetics of pH changes and the gradual secretion of enzymes, which could lead to the formation of some kind of coagulation in the casein samples. However, the time of digestion and the stirring applied could influence the outcomes.

In most cases, the use of an *in vivo* model to compare *in vitro* data in the same study is not possible. Some studies have used relevant human clinical data for reproducing *in vitro* studies. For example, Maathuis and co-workers determined the true ileal protein digestibility kinetics and DIAAS of a goat and cow milk-based infant formula, and human milk.²⁰⁴ The dynamic system tiny-TIM was used applying relevant infant (1–6 months) conditions of digestion. Over time, the digested compounds were dialyzed from the intestinal compartment and the content of nitrogen and AAs determined. The DIAAS for the goat milk formula, cow milk formula and human milk was 83%, 75%, and 77%, respectively, the latter being comparable to the value given by the FAO in humans.²⁰⁰ This suggests that the DIAAS can be determined by an *in vitro* dynamic model.

In general, the static models can provide a good approximation of overall protein digestion. The (semi)dynamic models have the potential to simulate the kinetics of protein digestion, in particular, when the gastric phase can induce structural changes in proteins. However, it is important to consider the digestion conditions in the (semi)dynamic models since the stirring mechanism has been observed to provide the main cause of difference from the *in vivo* data.

3.2 *In vivo–in vitro* correlation in lipid research

In vivo studies have usually assessed lipid breakdown by following the triglyceride appearance in blood, *i.e.* lipidemia. Although lipidemia is an indirect measure of lipid digestion, there is also an increasing interest in the study of the colloidal properties of lipids using, for example, MRI during gastric digestion to gain insights into gastric structural changes. This research has currently been of great interest since digestion of lipid is not only important in nutrient delivery and absorption but also plays a critical role in satiation and subsequent regulation of energy intake.⁷⁵

A few studies have investigated the *in vivo–in vitro* correlation. Golding *et al.* studied the free fatty acid (FFA) release in oil-in-water emulsions (stabilised by phospholipid, polysorbate, whey proteins and sodium stearyl lactylate) designed to exert specific gastric behaviours (stable, coalesced, partially coalesced and fully broken).²⁰⁵ This study was performed using a 2-state static digestion, a gastric phase (pH 1.9) and intestinal phase using a pH stat device controlled at pH 6.8, which enable the measurement of the extent of lipolysis. The authors showed that the low surface area induced by lipid coalescence or breaking, resulted in low lipolysis when compared to emulsions that were stable under gastric conditions. Three emulsions (phospholipids, sodium stearyl lactylate liquid oil and liquid oil/solid fat) were used in an *in vivo* study using healthy participants to investigate the impact on lipid absorption/metabolism. The rates of increase in triglyceride concentration in plasma after the consumption of the emulsions were partially correlated to the rates of FFAs released in the *in vitro* intestinal phase. However, there was a poor correlation with the emulsion that coalesced under simulated gastric conditions (*i.e.* emulsion with sodium stearyl lactylate liquid oil/solid fat). The *in vivo* results showed a delayed but fast intestinal lipid uptake in contrast to the slow lipolysis *in vitro*. The stirring applied in the static model and the use of a static gastric pH (1.9) could have influenced this outcome. The latter provides an overestimation of pepsin hydrolysis and limited action of the fungal gastric lipase at that pH. These conditions differed from the *in vivo* situation and therefore, could influence the gastric stability of the emulsions and the subsequent triglyceride appearance in blood. Indeed, the incorporation of solid fat into an acid-unstable emulsion induced phase separation observed by MRI, which delayed the emptying of lipid.²⁰⁶ Therefore, when studying the effect of lipid gastric stability on lipid digestion it is crucial to consider the physiologically relevant conditions of the gastric digestion that are better provided by (semi)dynamic models.

A semi-dynamic model was able to simulate the gastric restructuring that was observed in an *in vivo* study.⁷⁴ This model simulated the gradual pH decrease, the sequential addition of digestive enzymes and gastric fluid and the gastric emptying. The latter parameter was simulated according to a pre-set curve based on the *in vivo* study data²⁰⁷ and each aliquot that was taken simulating the gastric emptying underwent a static small intestinal digestion. The same



samples were tested in both studies; semi-solid (a mixture of cheese and yoghurt) and liquid (oil-in-water emulsion stabilised by milk proteins). The *in vivo* study, using MRI, showed phase-separation and sedimentation in the liquid and semi-solid samples, respectively. The same gastric behaviour was obtained in the *in vitro* model providing a good *in vivo*-*in vitro* correlation. However, the phase separation of the liquid sample was obtained in a later stage, which might be due to the complex peristaltic movements that were not well simulated in the gastric *in vitro* model used. Furthermore, in the *in vivo* study, the semi-solid sample induced substantially more fullness than the liquid sample after just 15 min of digestion. This could potentially be explained by the high levels of proteins and lipids released from the semi-solid sample *in vitro*. This study shows how *in vivo* and *in vitro* models can complement one another to gain mechanistic insights into *in vivo* outcomes, which could be highly complex to obtain using only *in vivo* data. However, experiments need to be performed using relevant *in vitro* models based on the research question of interest.

In general, the static models can predict trends of the overall lipid digestion. However, semi-dynamic and dynamic models can be recommended as the most appropriate model to simulate the gastric colloidal stability of lipids that occurs *in vivo*.

3.3 *In vivo*-*in vitro* correlation in carbohydrate research

In clinical studies, the digestion of digestible carbohydrates, mainly starch, is followed by the rate of postprandial glucose appearance in blood, *i.e.* glycaemia. The most popular metric to classify the *in vivo* availability of digestible carbohydrate sources is the glycaemic index.²⁰⁸ This is a kinetic parameter that measures the postprandial incremental area under the curve (AUC) for 120 min in a test food when compared to a reference food (white bread or glucose solution) with the equivalent amount of available carbohydrate (ISO, 2010). The study of the postprandial glucose of foods is of high interest since the consumption of food products containing slowly digested starch has been associated with health benefits such as the decreased risk of type II diabetes.²⁰⁹

Static *in vitro* models have been widely applied to study starch digestibility to predict the glycaemic response to foods. The study of Jenkins *et al.* is one of the first to investigate the correlation between the glycaemic index of foods and their *in vitro* starch hydrolysis.²⁰⁸ The *in vitro* static digestion included pooled human saliva and post-prandial jejunal secretions using dialysis bags. The authors found a high positive correlation between the concentration of carbohydrate liberated *in vitro* and the glycaemic index at 1 hour ($r = 0.8627$) and 5 hours ($r = 0.8618$) of digestion in foods with a different starch source. Englyst *et al.* developed an enzymatic *in vitro* method to classify food carbohydrates based on their digestibility,²¹⁰ where rapidly available glucose was defined as the fraction of glucose that was obtained at 20 min of hydrolysis and slowly available glucose was related to the fraction obtained at 120 min of hydrolysis. This *in vitro* method pro-

vided a significant correlation ($r = 0.981$) between the proportions of rapidly digestive starch when compared to the glycaemic index values obtained *in vivo*.²¹¹ Similarly, Goñi *et al.* developed a static *in vitro* procedure to follow the rate of starch digestion of a series of 10 starchy foods.²¹² The authors showed a possible estimation of glycaemic index based on the time monitoring of starch hydrolysis, considering 90 min of intestinal digestion as the best correlation ($r = 0.909$) with the glucose responses (AUCs for 120 min).

There is a multitude of other *in vitro* carbohydrate digestion models that can predict the glycaemic properties of foods.^{213,214} However, they do not simulate the glycaemic response over time, which needs to take into account the rate of gastric emptying. The rate of digestion and absorption of glucose is controlled by the pancreatic α -amylase accessibility and amount of starch present in the duodenum. The latter is very much dictated by gastric emptying. Furthermore, salivary α -amylase can play a significant role in gastric starch hydrolysis since it is still active at the highest pH values found in the early stage of gastric digestion.¹²⁹ Therefore, the simplification of a static gastric pH or its absence could lead to underestimation of starch hydrolysis.

Some dynamic *in vitro* models have been used to calculate glycaemic index based on the kinetics of digestible starch hydrolysis in the small intestine and correlate with *in vivo* data. For example, Ballance *et al.* investigated starch digestion in six cereal-based meals (white bread, cornflakes, micronized barley flakes, extruded barley flakes, oat flour and extruded oat) performed by a dynamic gastric digestion using the DGM and static intestinal digestion for 60 min.⁹³ The samples were chewed by a subject and expectorated. There was no significant difference in the glycaemic index between the calculated *in vitro* values and the corresponding *in vivo* values from the literature for cornflakes and the two barley products. The two barley flake samples (micronized and extruded) were also assessed *in vivo*. The micronised barley flake meal had a low digestible starch content, peak rate of starch hydrolysis and a long duration of starch digestion in both *in vitro* and *in vivo*. The *in vitro* calculated glycaemic index was 66, which was similar to that calculated *in vivo*. However, the peak of the glucose curve in plasma *in vivo* occurred earlier than the one predicted *in vitro*. It is important to highlight that the supernatant of the digesta samples was treated with amyloglucosidase to convert the starch oligomers to glucose and, therefore simulating the further hydrolysis that occurs in the brush border. Therefore, the *in vitro* data represented the potential plasma curves. This study shows the potential of the dynamic *in vitro* model to simulate the *in vivo* glycaemic response of a simple starch-rich cereal.

The multi-compartmental digestion system, TIM-1, has been used to examine the impact of fermented barley and oat microstructure on the rate of *in vitro* starch hydrolysis,¹³³ and compared to the glycaemic index values of the human study performed with identical raw material and tempe fermentations.²¹⁵ The AUC calculated from the starch hydrolysis curves, measured as maltose generated during digestion, in barley was



40% of that for oat tempe. Similarly, in the parallel human study, the AUC for plasma glucose for barley was 46% of the AUC for oat tempe. The findings showed that both the oat and barley samples showed an increase in starch hydrolysis within the 60 min in contrast to the rise of blood glucose that occurred within the 30 min. However, after that increase the levels reached a plateau and decreased steadily both *in vitro* and *in vivo*. Therefore, the close agreement of the *in vitro*–*in vivo* data indicates this dynamic model as a potential tool of predicting the rates and extent of glucose in plasma. The TIM model has been validated with clinical data on carbohydrate digestion, against different *in vivo* plasma glucose response curves after the intake of carbohydrate food products ($R = 0.91$) and named TIM-Carbo technology.²¹⁶

The use of *in vitro* models has been seen to provide a valuable tool to give indications about glycaemic index. However, most of the studies have used individual food products that are commonly consumed as part of a complex meal. For instance, corn flakes are usually consumed with milk. The co-ingestion of other macronutrients will influence the emptying rate of carbohydrate foods and, consequently the glycaemic response.²¹⁷ Consequently, it is important to bear in mind, that the gastric emptying of foods can change their inherent glycaemic index.

3.4 *In vivo*–*in vitro* correlation in micronutrients and phytochemicals research

Bioavailability of micronutrients and phytochemicals *in vivo* is estimated using animal models or in human studies by measuring long-term plasma responses. The absorption efficiency of food micronutrients and phytochemicals is highly variable and dependent on a range of factors such as colonic changes and transport metabolism. Some of them are highly absorbed in the small intestine (*i.e.* carotenoids) whereas the colonic fermentation is highly important in others (*i.e.* polyphenols).

Reboul *et al.* compared the bioaccessibility of the micellar fraction of food sources rich in carotenoids (α - and γ -tocopherol, β -carotene, lycopene, and lutein) between an *in vitro* static model²¹⁸ and *in vivo*.²¹⁹ The results showed a high correlation ($r = 0.90$) between the *in vitro*–*in vivo* bioaccessibility. However, spinach lutein bioaccessibility was about 5-fold higher *in vitro* than *in vivo*. The authors also compared the *in vitro* bioaccessibility values obtained with the bioavailability values measured in other published human studies using similar test meals, obtaining a significant relationship ($r = 0.98$). However, the range of bioavailability ratios observed in human studies were very wide.

The digestion of polyphenols is dictated by the extent of transformation into different metabolites. A small amount of ingested polyphenols are absorbed in the small intestine and converted by enzymes in brush border. Many polyphenols reach the colon where several microbial metabolites are formed and can be absorbed. Vetrani *et al.* compared the *in vitro* microbial phenolic metabolite profile of a series of high polyphenol content foods with the metabolites that were

excreted by subjects after consuming the same foods in an 8-week study.²²⁰ There was a moderate correlation ($r = 0.280$) for the main 15 metabolites between the average calculation of 6-hour colonic metabolites from *in vitro* colon model and 24-hour urinary.

Verwei *et al.* developed an approach to predict human serum concentrations after the consumption of folate-fortified milk products.²²¹ The GI digestion was performed using a TIM-1 providing folate bioaccessibility data and Caco-2 cells were used to provide *in vitro* data about the folate absorption. This data was used as input for a mathematical (*in silico*) model to predict serum concentrations. The *in vitro*–*in silico* approach was compared to the *in vivo* data using the same fortified milks consumed for 4 weeks. The predicted serum folate concentrations would increase from 9.2 nmol L⁻¹ to 14.6 nmol L⁻¹ and 15.3 nmol L⁻¹ for UHT and pasteurized milk, respectively, whereas the serum concentrations increased to 14.1 and 13.9 nmol L⁻¹ *in vivo*. According to the authors, this *in vitro*–*in silico* approach provided a correct prediction of serum folate concentrations in humans.

Overall, the high complexity and variability of the bioavailability observed in micronutrients and phytochemicals leads to the use of specific approaches in each case to try to enhance the *in vivo*–*in vitro* correlation. The review by Etcheverry *et al.* provides more detailed information.²²²

4 Conclusions

In this article, we have reviewed the wide range of approaches to simulate the human GI tract. It is evident that although progress has been made towards more physiologically relevant and standardised approaches such as those developed by the Infogest Network, there is still a wide range of models being used for different purposes. One of the key recent developments has been the extension of models to enable the simulation of the GI environment in different segments of the population. These have seen particular focus on infants and the elderly but a number of other groups are also being studied. In addition to this approach targeting more specific demographic groups, the use of combinations of *in silico*, *in vitro* and *in vivo* models offers many opportunities for more powerful predictive scenarios.

A model is only useful if it is either predictive or offers mechanistic insight. In either case, models need to be validated against *in vivo* data and this can often be an obstacle due to limitations in the availability of relevant data. In particular, human studies tend to measure bioactive concentrations in blood and not in the GI tract whereas *in vitro* studies often only produce data on release into the gut lumen. This is the difficulty of comparing bioaccessibility as generated *in vitro* with bioavailability as generated *in vivo*. In general, bioaccessibility tends to overestimate bioavailability. Indeed, the luminal hydrolysis by the brush border enzymes and the mucosal absorption might be considered as limiting factors, which can be considered for further improvements to *in vitro*



models. It is crucial to build up a proper correlation between *in vitro* and *in vivo* to better elucidate nutrient digestion mechanisms *in vitro* and, consequently, gain understanding of the linked physiological responses.

It is apparent that the models being used are increasingly being validated with *in vivo* data and this bodes well for the future. In particular, the combination of artificial intelligent methods and validated *in vitro* models offers the possibility of replacing animal and human studies in some areas of research.

Abbreviations

GI	Gastrointestinal
UHT	Ultra-high temperature
AA	Amino acid
DGM	Dynamic gastric model
HGS	Human gastric simulator
BBM	Brush border membrane
CFD	Computational fluid dynamics
DIAAS	Digestible indispensable amino acid score
MRI	Magnetic resonance imaging
FFA	Free fatty acid
AUC	Area under the curve

Conflicts of interest

The authors have no conflicts of interest to declare.

References

- 1 R. Lucas-Gonzalez, M. Viuda-Martos, J. A. Perez-Alvarez and J. Fernandez-Lopez, In vitro digestion models suitable for foods: Opportunities for new fields of application and challenges, *Food Res. Int.*, 2018, **107**, 423–436.
- 2 D. J. McClements and S.-F. Peng, Current status in our understanding of physicochemical basis of bioaccessibility, *Curr. Opin. Food Sci.*, 2020, **31**, 57–62.
- 3 F. Granado-Lorencio, E. Donoso-Navarro, I. Blanco-Navarro and B. Perez-Sacristan, Predictive value of in vitro digestion models: in vivo validation using absorption modifiers, *Ann. Nutr. Metab.*, 2011, **58**, 102–102.
- 4 T. Bohn, F. Carriere, L. Day, A. Deglaire, L. Egger, D. Freitas, M. Golding, S. Le Feunteun, A. Macierzanka, O. Menard, B. Miralles, A. Moscovici, R. Portmann, I. Recio, D. Remond, V. Sante-Lhoutelier, T. J. Wooster, U. Lesmes, A. R. Mackie and D. Dupont, Correlation between in vitro and in vivo data on food digestion. What can we predict with static in vitro digestion models?, *Crit. Rev. Food Sci. Nutr.*, 2018, **58**, 2239–2261.
- 5 N. M. Anson, R. van den Berg, R. Havenaar, A. Bast and G. Haenen, Bioavailability of ferulic acid is determined by its bioaccessibility, *J. Cereal Sci.*, 2009, **49**, 296–300.
- 6 M. Hajishafiee, V. Bitarafan and C. Feinle-Bisset, Gastrointestinal Sensing of Meal-Related Signals in Humans, and Dysregulations in Eating-Related Disorders, *Nutrients*, 2019, **11**, 1298.
- 7 A. Okada, M. Honma, S. Nomura and Y. Yamada, Oral behavior from food intake until terminal swallow, *Physiol. Behav.*, 2007, **90**, 172–179.
- 8 M. Assad-Bustillos, J. Palier, H. Rabesona, Y. Choiset, G. Della Valle and G. Feron, Role of the bolus degree of structure on the protein digestibility during in vitro digestion of a pea protein-fortified sponge cake chewed by elderly, *J. Texture Stud.*, 2020, **51**, 134–143.
- 9 M. Fried, S. Abramson and J. H. Meyer, Passage of salivary amylase through the stomach in humans, *Dig. Dis. Sci.*, 1987, **32**, 1097–1103.
- 10 L. Sams, J. Paume, J. Giallo and F. Carriere, Relevant pH and lipase for in vitro models of gastric digestion, *Food Funct.*, 2016, **7**, 30–45.
- 11 D. W. Piper and B. H. Fenton, pH stability and activity curves of pepsin with special reference to their clinical importance, *Gut*, 1965, **6**, 506–508.
- 12 L. Marciani, P. A. Gowland, R. C. Spiller, P. Manoj, R. J. Moore, P. Young and A. J. Fillery-Travis, Effect of meal viscosity and nutrients on satiety, intragastric dilution, and emptying assessed by MRI, *Am. J. Physiol.: Gastrointest. Liver Physiol.*, 2001, **280**, G1227–G1233.
- 13 A. Brodtkorb, L. Egger, M. Alminger, P. Alvito, R. Assunção, S. Ballance, T. Bohn, C. Bourlieu-Lacanal, R. Boutrou, F. Carrière, A. Clemente, M. Corredig, D. Dupont, C. Dufour, C. Edwards, M. Golding, S. Karakaya, B. Kirkhus, S. Le Feunteun, U. Lesmes, A. Macierzanka, A. R. Mackie, C. Martins, S. Marze, D. J. McClements, O. Ménard, M. Minekus, R. Portmann, C. N. Santos, I. Souchon, R. P. Singh, G. E. Vegarud, M. S. J. Wickham, W. Weitschies and I. Recio, INFOGEST static in vitro simulation of gastrointestinal food digestion, *Nat. Protoc.*, 2019, **14**, 991–1014.
- 14 L. Egger, O. Menard, C. Delgado-Andrade, P. Alvito, R. Assuncao, S. Balance, R. Barbera, A. Brodtkorb, T. Cattenoz, A. Clemente, I. Comi, D. Dupont, G. Garcia-Llatas, M. J. Lagarda, S. Le Feunteun, L. JanssenDuijghuijsen, S. Karakaya, U. Lesmes, A. R. Mackie, C. Martins, A. Meynier, B. Miralles, B. S. Murray, A. Pihlanto, G. Picariello, C. N. Santos, S. Simsek, I. Recio, N. Rigby, L. E. Rioux, H. Stoffers, A. Tavares, L. Tavares, S. Turgeon, E. K. Ulleberg, G. E. Vegarud, G. Vergeres and R. Portmann, The harmonized INFOGEST in vitro digestion method: From knowledge to action, *Food Res. Int.*, 2016, **88**, 217–225.
- 15 L. Egger, O. Menard, C. Baumann, D. Duerr, P. Schlegel, P. Stoll, G. Vergeres, D. Dupont and R. Portmann, Digestion of milk proteins: Comparing static and dynamic in vitro digestion systems with in vivo data, *Food Res. Int.*, 2019, **118**, 32–39.
- 16 S. J. Hur, B. O. Lim, E. A. Decker and D. J. McClements, In vitro human digestion models for food applications, *Food Chem.*, 2011, **125**, 1–12.



- 17 J. Gass, H. Vora, A. F. Hofmann, G. M. Gray and C. Khosla, Enhancement of dietary protein digestion by conjugated bile acids, *Gastroenterology*, 2007, **133**, 16–23.
- 18 G. Mandalari, A. M. Mackie, N. M. Rigby, M. S. Wickham and E. N. Mills, Physiological phosphatidylcholine protects bovine beta-lactoglobulin from simulated gastrointestinal proteolysis, *Mol. Nutr. Food Res.*, 2009, **53**(Suppl 1), S131–S139.
- 19 A. Macierzanka, A. Torcello-Gomez, C. Jungnickel and J. Maldonado-Valderrama, Bile salts in digestion and transport of lipids, *Adv. Colloid Interface Sci.*, 2019, **274**, 102045.
- 20 M. Minekus, M. Alving, P. Alvito, S. Ballance, T. Bohn, C. Bourlieu, F. Carriere, R. Boutrou, M. Corredig, D. Dupont, C. Dufour, L. Egger, M. Golding, S. Karakaya, B. Kirkhus, S. Le Feunteun, U. Lesmes, A. Macierzanka, A. Mackie, S. Marze, D. J. McClements, O. Menard, I. Recio, C. N. Santos, R. P. Singh, G. E. Vegarud, M. S. Wickham, W. Weitschies and A. Brodtkorb, A standardised static in vitro digestion method suitable for food - an international consensus, *Food Funct.*, 2014, **5**, 1113–1124.
- 21 A. I. Mulet-Cabero, L. Egger, R. Portmann, O. Menard, S. Marze, M. Minekus, S. Le Feunteun, A. Sarkar, M. M. Grundy, F. Carriere, M. Golding, D. Dupont, I. Recio, A. Brodtkorb and A. Mackie, A standardised semi-dynamic in vitro digestion method suitable for food - an international consensus, *Food Funct.*, 2020, **11**, 1702–1720.
- 22 L. Sams, S. Amara, P. Mansuelle, R. Puppo, R. Lebrun, J. Paume, J. Giallo and F. Carriere, Characterization of pepsin from rabbit gastric extract, its action on beta-casein and the effects of lipids on proteolysis, *Food Funct.*, 2018, **9**, 5975–5988.
- 23 A. Roussel, S. Canaan, M. P. Egloff, M. Riviere, L. Dupuis, R. Verger and C. Cambillau, Crystal structure of human gastric lipase and model of lysosomal acid lipase, two lipolytic enzymes of medical interest, *J. Biol. Chem.*, 1999, **274**, 16995–17002.
- 24 P. Capolino, C. Guérin, J. Paume, J. Giallo, J. M. Ballester, J. F. Cavalier and F. Carrière, In Vitro Gastrointestinal Lipolysis: Replacement of Human Digestive Lipases by a Combination of Rabbit Gastric and Porcine Pancreatic Extracts, *Food Dig.*, 2011, **2**, 43–51.
- 25 A. Macierzanka, A. I. Sancho, E. N. C. Mills, N. M. Rigby and A. R. Mackie, Emulsification alters simulated gastrointestinal proteolysis of β -casein and β -lactoglobulin, *Soft Matter*, 2009, **5**, 538–550.
- 26 N. H. Zangenberg, A. Mullertz, H. G. Kristensen and L. Hovgaard, A dynamic in vitro lipolysis model. I. Controlling the rate of lipolysis by continuous addition of calcium, *Eur. J. Pharm. Sci.*, 2001, **14**, 115–122.
- 27 E. K. Eriksen, H. Holm, E. Jensen, R. Aaboe, T. G. Devold, M. Jacobsen and G. E. Vegarud, Different digestion of caprine whey proteins by human and porcine gastrointestinal enzymes, *Br. J. Nutr.*, 2010, **104**, 374–381.
- 28 K. E. Aarak, B. Kirkhus, H. Holm, G. Vogt, M. Jacobsen and G. E. Vegarud, Release of EPA and DHA from salmon oil - a comparison of in vitro digestion with human and porcine gastrointestinal enzymes, *Br. J. Nutr.*, 2013, **110**, 1402–1410.
- 29 T. Asledottir, T. T. Le, B. Petrat-Melin, T. G. Devold, L. B. Larsen and G. E. Vegarud, Identification of bioactive peptides and quantification of β -casomorphin-7 from bovine β -casein A1, A2 and I after ex vivo gastrointestinal digestion, *Int. Dairy J.*, 2017, **71**, 98–106.
- 30 E. K. Ulleberg, I. Comi, H. Holm, E. B. Herud, M. Jacobsen and G. E. Vegarud, Human Gastrointestinal Juices Intended for Use in In Vitro Digestion Models, *Food Dig.*, 2011, **2**, 52–61.
- 31 C. Li, W. Yu, P. Wu and X. D. Chen, Current in vitro digestion systems for understanding food digestion in human upper gastrointestinal tract, *Trends Food Sci. Technol.*, 2020, **96**, 114–126.
- 32 J. D. Astwood, J. N. Leach and R. L. Fuchs, Stability of food allergens to digestion in vitro, *Nat. Biotechnol.*, 1996, **14**, 1269–1273.
- 33 K. Thomas, M. Aalbers, G. A. Bannon, M. Bartels, R. J. Dearman, D. J. Esdaile, T. J. Fu, C. M. Glatt, N. Hadfield, C. Hatzos, S. L. Hefle, J. R. Heylings, R. E. Goodman, B. Henry, C. Herouet, M. Holsapple, G. S. Ladics, T. D. Landry, S. C. MacIntosh, E. A. Rice, L. S. Privalle, H. Y. Steiner, R. Teshima, R. van Ree, M. Woolhiser and J. Zawodny, A multi-laboratory evaluation of a common in vitro pepsin digestion assay protocol used in assessing the safety of novel proteins, *Regul. Toxicol. Pharmacol.*, 2004, **39**, 87–98.
- 34 H. Naegeli, A. N. Birch, J. Casacuberta, A. De Schrijver, M. A. Gralak, P. Guerche, H. Jones, B. Manachini, A. Messean, E. E. Nielsen, F. Nogue, C. Robaglia, N. Rostoks, J. Sweet, C. Tebbe, F. Visioli, J. M. Wal, P. Eigenmann, M. Epstein, K. Hoffmann-Sommergruber, F. Koning, M. Lovik, C. Mills, F. J. Moreno, H. van Loveren, R. Selb, A. F. Dumont and E. P. G. Modified, Guidance on allergenicity assessment of genetically modified plants, *EFSA J.*, 2017, **15**, 4862–4911.
- 35 O. Menard, C. Bourlieu, S. C. De Oliveira, N. Dellarosa, L. Laghi, F. Carriere, F. Capozzi, D. Dupont and A. Deglaire, A first step towards a consensus static in vitro model for simulating full-term infant digestion, *Food Chem.*, 2018, **240**, 338–345.
- 36 C. S. Levi and U. Lesmes, Bi-compartmental elderly or adult dynamic digestion models applied to interrogate protein digestibility, *Food Funct.*, 2014, **5**, 2402–2409.
- 37 C. S. Levi, N. Goldstein, R. Portmann and U. Lesmes, Emulsion and protein degradation in the elderly: Qualitative insights from a study coupling a dynamic in vitro digestion model with proteomic analyses, *Food Hydrocolloids*, 2017, **69**, 393–401.
- 38 C. Bourlieu, O. Menard, K. Bouzerzour, G. Mandalari, A. Macierzanka, A. R. Mackie and D. Dupont, Specificity of infant digestive conditions: some clues for developing



- relevant in vitro models, *Crit. Rev. Food Sci. Nutr.*, 2014, **54**, 1427–1457.
- 39 C. S. Levi, P. Alvito, A. Andrés, R. Assunção, R. Barberá, S. Blanquet-Diot, C. Bourlieu, A. Brodkorb, A. Cilla, A. Deglaire, S. Denis, D. Dupont, A. Heredia, S. Karakaya, C. V. L. Giosafatto, L. Mariniello, C. Martins, O. Ménard, S. N. El, G. E. Vegarud, E. Ulleberg and U. Lesmes, Extending in vitro digestion models to specific human populations: Perspectives, practical tools and bio-relevant information, *Trends Food Sci. Technol.*, 2017, **60**, 52–63.
- 40 T. T. P. Nguyen, B. Bhandari, J. Cichero and S. Prakash, A comprehensive review on in vitro digestion of infant formula, *Food Res. Int.*, 2015, **76**, 373–386.
- 41 M. Christian, C. Edwards and L. T. Weaver, Starch digestion in infancy, *J. Pediatr. Gastroenterol. Nutr.*, 1999, **29**, 116–124.
- 42 L. Poquet and T. J. Wooster, Infant digestion physiology and the relevance of in vitro biochemical models to test infant formula lipid digestion, *Mol. Nutr. Food Res.*, 2016, **60**, 1876–1895.
- 43 D. W. Piper and B. H. Fenton, pH stability and activity curves of pepsin with special reference to their clinical importance, *Gut*, 1965, **6**, 506–508.
- 44 D. Kamstrup, R. Berthelsen, P. J. Sassene, A. Selen and A. Mullertz, In Vitro Model Simulating Gastro-Intestinal Digestion in the Pediatric Population (Neonates and Young Infants), *AAPS PharmSciTech*, 2017, **18**, 317–329.
- 45 J. Sarles, H. Moreau and R. Verger, Human gastric lipase: ontogeny and variations in children, *Acta Paediatr.*, 1992, **81**, 511–513.
- 46 E. Lebenthal, P. C. Lee and L. A. Heitlinger, Impact of development of the gastrointestinal tract on infant feeding, *J. Pediatr.*, 1983, **102**, 1–9.
- 47 C. Bourlieu, O. Menard, A. De La Chevasnerie, L. Sams, F. Rousseau, M. N. Madec, B. Robert, A. Deglaire, S. Pezennec, S. Bouhallab, F. Carriere and D. Dupont, The structure of infant formulas impacts their lipolysis, proteolysis and disintegration during in vitro gastric digestion, *Food Chem.*, 2015, **182**, 224–235.
- 48 D. Bosscher, M. Van Caillie-Bertrand, H. Robberecht, K. Van Dyck, R. Van Cauwenbergh and H. Deelstra, In vitro availability of calcium, iron, and zinc from first-age infant formulae and human milk, *J. Pediatr. Gastroenterol. Nutr.*, 2001, **32**, 54–58.
- 49 D. E. W. Chatterton, J. T. Rasmussen, C. W. Heegaard, E. S. Sørensen and T. E. Petersen, In vitro digestion of novel milk protein ingredients for use in infant formulas: Research on biological functions, *Trends Food Sci. Technol.*, 2004, **15**, 373–383.
- 50 D. Dupont, G. Mandalari, D. Molle, J. Jardin, J. Leonil, R. M. Faulks, M. S. J. Wickham, E. N. C. Mills and A. R. Mackie, Comparative resistance of food proteins to adult and infant in vitro digestion models, *Mol. Nutr. Food Res.*, 2010, **54**, 767–780.
- 51 S. Cattaneo, M. Stuknyte, F. Masotti and I. De Noni, Protein breakdown and release of beta-casomorphins during in vitro gastro-intestinal digestion of sterilised model systems of liquid infant formula, *Food Chem.*, 2017, **217**, 476–482.
- 52 T. T. P. Nguyen, B. Bhandari, J. Cichero and S. Prakash, Gastrointestinal digestion of dairy and soy proteins in infant formulas: An in vitro study, *Food Res. Int.*, 2015, **76**, 348–358.
- 53 C. Shani-Levi, S. Levi-Tal and U. Lesmes, Comparative performance of milk proteins and their emulsions under dynamic in vitro adult and infant gastric digestion, *Food Hydrocolloids*, 2013, **32**, 349–357.
- 54 Y. Joubran, A. Moscovici and U. Lesmes, Antioxidant activity of bovine alpha lactalbumin Maillard products and evaluation of their in vitro gastro-duodenal digestive proteolysis, *Food Funct.*, 2015, **6**, 1229–1240.
- 55 C. H. Versantvoort, A. G. Oomen, E. Van de Kamp, C. J. Rempelberg and A. J. Sips, Applicability of an in vitro digestion model in assessing the bioaccessibility of mycotoxins from food, *Food Chem. Toxicol.*, 2005, **43**, 31–40.
- 56 C. Dall'Asta, P. Florio, A. M. Lammardo, B. Prandi, T. Mazzeo, A. Budelli and N. Pellegrini, Development of an in vitro digestive model for studying the peptide profile of breast milk, *Int. J. Food Sci. Nutr.*, 2015, **66**, 409–415.
- 57 M. Klitgaard, P. J. Sassene, A. Selen, A. Mullertz and R. Berthelsen, Studying furosemide solubilization using an in vitro model simulating gastrointestinal digestion and drug solubilization in neonates and young infants, *Eur. J. Pharm. Sci.*, 2017, **109**, 191–199.
- 58 A. A. O. Xavier, J. E. Garrido-Lopez, J. Aguayo-Maldonado, J. Garrido-Fernandez, J. Fontecha and A. A. Perez-Galvez, In Vitro Digestion of Human Milk: Influence of the Lactation Stage on the Micellar Carotenoids Content, *Antioxidants*, 2019, **8**, 291.
- 59 D. Remond, D. R. Shahar, D. Gille, P. Pinto, J. Kachal, M. A. Peyron, C. N. Dos Santos, B. Walther, A. Bordoni, D. Dupont, L. Tomas-Cobos and G. Vergeres, Understanding the gastrointestinal tract of the elderly to develop dietary solutions that prevent malnutrition, *Oncotarget*, 2015, **6**, 13858–13898.
- 60 M. Feldman, B. Cryer, K. E. McArthur, B. A. Huet and E. Lee, Effects of aging and gastritis on gastric acid and pepsin secretion in humans: a prospective study, *Gastroenterology*, 1996, **110**, 1043–1052.
- 61 S. Denis, T. Sayd, A. Georges, C. Chambon, S. Chalancon, V. Sante-Lhoutellier and S. Blanquet-Diot, Digestion of cooked meat proteins is slightly affected by age as assessed using the dynamic gastrointestinal TIM model and mass spectrometry, *Food Funct.*, 2016, **7**, 2682–2691.
- 62 M. A. Peyron, V. Santé-Lhoutellier, D. Dardevet, M. Hennequin, D. Rémond, O. François and A. Woda, Addressing various challenges related to food bolus and nutrition with the AM2 mastication simulator, *Food Hydrocolloids*, 2019, **97**, 105229.
- 63 J.-R. Malagelada, V. L. Go and W. Summerskill, Different gastric, pancreatic, and biliary responses to solid-liquid or homogenized meals, *Dig. Dis. Sci.*, 1979, **24**, 101–110.



- 64 J. D. Gardner, A. A. Ciociola and M. Robinson, Measurement of meal-stimulated gastric acid secretion by in vivo gastric autotitration, *J. Appl. Physiol.*, 2002, **92**, 427–434.
- 65 B. L. Dekkers, E. Kolodziejczyk, S. Acquistapace, J. Engmann and T. J. Wooster, Impact of gastric pH profiles on the proteolytic digestion of mixed betalg-Xanthan biopolymer gels, *Food Funct.*, 2016, **7**, 58–68.
- 66 W. Liu, D. Fu, X. Zhang, J. Chai, S. Tian and J. Han, Development and validation of a new artificial gastric digestive system, *Food Res. Int.*, 2019, **122**, 183–190.
- 67 A. I. Mulet-Cabero, A. Torcello-Gomez, S. Saha, A. R. Mackie, P. J. Wilde and A. Brodkorb, Impact of caseins and whey proteins ratio and lipid content on in vitro digestion and ex vivo absorption, *Food Chem.*, 2020, **319**, 126514.
- 68 Y. Boirie, M. Dangin, P. Gachon, M.-P. Vasson, J.-L. Maubois and B. Beaufrère, Slow and fast dietary proteins differently modulate postprandial protein accretion, *Proc. Natl. Acad. Sci. U. S. A.*, 1997, **94**, 14930–14935.
- 69 A.-I. Mulet-Cabero, A. R. Mackie, P. J. Wilde, M. A. Fenelon and A. Brodkorb, Structural mechanism and kinetics of in vitro gastric digestion are affected by process-induced changes in bovine milk, *Food Hydrocolloids*, 2019, **86**, 172–183.
- 70 C. C. M. van den Braak, M. Klebach, E. Abrahamse, M. Minor, Z. Hofman, J. Knol and T. Ludwig, A novel protein mixture containing vegetable proteins renders enteral nutrition products non-coagulating after in vitro gastric digestion, *Clin. Nutr.*, 2013, **32**, 765–771.
- 71 F. Nau, K. Nyemb-Diop, V. Lechevalier, J. Floury, C. Serrière, N. Stroebinger, T. Boucher, C. Guérin-Dubiard, M. J. Ferrua and D. Dupont, Spatial-temporal changes in pH, structure and rheology of the gastric chyme in pigs as influenced by egg white gel properties, *Food Chem.*, 2019, **280**, 210–220.
- 72 M. Vardakou, A. Mercuri, T. A. Naylor, D. Rizzo, J. M. Butler, P. C. Connolly, M. S. J. Wickham and R. M. Faulks, Predicting the human in vivo performance of different oral capsule shell types using a novel in vitro dynamic gastric model, *Int. J. Pharm.*, 2011, **419**, 192–199.
- 73 F. B. Kong and R. P. Singh, A Human Gastric Simulator (HGS) to Study Food Digestion in Human Stomach, *J. Food Sci.*, 2010, **75**, E627–E635.
- 74 A.-I. Mulet-Cabero, N. M. Rigby, A. Brodkorb and A. R. Mackie, Dairy food structures influence the rates of nutrient digestion through different in vitro gastric behaviour, *Food Hydrocolloids*, 2017, **67**, 63–73.
- 75 C. Feinle, M. Christen, D. Grundy, H. Faas, O. Meier, B. Otto and M. Fried, Effects of duodenal fat, protein or mixed-nutrient infusions on epigastric sensations during sustained gastric distension in healthy humans, *Neurogastroenterol. Motil.*, 2002, **14**, 205–213.
- 76 Y. Cohen, M. Levi, U. Lesmes, M. Margier, E. Reboul and Y. D. Livney, Re-assembled casein micelles improve in vitro bioavailability of vitamin D in a Caco-2 cell model, *Food Funct.*, 2017, **8**, 2133–2141.
- 77 L. Fahoum, A. Moscovici, S. David, R. Shaoul, G. Rozen, E. G. Meyron-Holtz and U. Lesmes, Digestive fate of dietary carrageenan: Evidence of interference with digestive proteolysis and disruption of gut epithelial function, *Mol. Nutr. Food Res.*, 2017, **61**, 1600545.
- 78 A.-S. Stübler, U. Lesmes, V. Heinz, C. Rauh, A. Shpigelman and K. Aganovic, Digestibility, antioxidative activity and stability of plant protein-rich products after processing and formulation with polyphenol-rich juices: kale and kale–strawberry as a model, *Eur. Food Res. Technol.*, 2019, **245**, 2499–2514.
- 79 G. A. van Aken, E. Bomhof, F. D. Zoet, M. Verbeek and A. Oosterveld, Differences in in vitro gastric behaviour between homogenized milk and emulsions stabilised by Tween 80, whey protein, or whey protein and caseinate, *Food Hydrocolloids*, 2011, **25**, 781–788.
- 80 A. Ferreira-Lazarte, A. Montilla, A. I. Mulet-Cabero, N. Rigby, A. Olano, A. Mackie and M. Villamiel, Study on the digestion of milk with prebiotic carbohydrates in a simulated gastrointestinal model, *J. Funct. Foods*, 2017, **33**, 149–154.
- 81 Y. C. Luiking, E. Abrahamse, T. Ludwig, Y. Boirie and S. Verlaan, Protein type and caloric density of protein supplements modulate postprandial amino acid profile through changes in gastrointestinal behaviour: A randomized trial, *Clin. Nutr.*, 2016, **35**, 48–58.
- 82 A. Woda, A. Mishellany-Dutour, L. Batier, O. François, J. Meunier, B. Reynaud, M. Alric and M.-A. Peyron, Development and validation of a mastication simulator, *J. Biomech.*, 2010, **43**, 1667–1673.
- 83 A. N. Payne, A. Zihler, C. Chassard and C. Lacroix, Advances and perspectives in in vitro human gut fermentation modeling, *Trends Biotechnol.*, 2012, **30**, 17–25.
- 84 A. Tharakan, I. Norton, P. Fryer and S. Bakalis, Mass transfer and nutrient absorption in a simulated model of small intestine, *J. Food Sci.*, 2010, **75**, E339–E346.
- 85 N. D. Wright, F. Kong, B. S. Williams and L. Fortner, A human duodenum model (HDM) to study transport and digestion of intestinal contents, *J. Food Eng.*, 2016, **171**, 129–136.
- 86 M. Wickham, R. Faulks, J. Mann and G. Mandalari, The design, operation, and application of a dynamic gastric model, *Dissolution Technol.*, 2012, **19**, 15–22.
- 87 M. Vardakou, A. Mercuri, S. A. Barker, D. Q. Craig, R. M. Faulks and M. S. Wickham, Achieving antral grinding forces in biorelevant in vitro models: comparing the USP dissolution apparatus II and the dynamic gastric model with human in vivo data, *AAPS PharmSciTech*, 2011, **12**, 620–626.
- 88 L. Marciani, P. A. Gowland, A. Fillery-Travis, P. Manoj, J. Wright, A. Smith, P. Young, R. Moore and R. C. Spiller, Assessment of antral grinding of a model solid meal with echo-planar imaging, *Am. J. Physiol.: Gastrointest. Liver Physiol.*, 2001, **280**, G844–G849.



- 89 G. E. Fraser, H. W. Bennett, K. B. Jaceldo and J. Sabaté, Effect on body weight of a free 76 kilojoule (320 calorie) daily supplement of almonds for six months, *J. Am. Coll. Nutr.*, 2002, **21**, 275–283.
- 90 G. Mandalari, M. M.-L. Grundy, T. Grassby, M. L. Parker, K. L. Cross, S. Chessa, C. Bisignano, D. Barreca, E. Bellocco and G. Lagana, The effects of processing and mastication on almond lipid bioaccessibility using novel methods of in vitro digestion modelling and micro-structural analysis, *Br. J. Nutr.*, 2014, **112**, 1521–1529.
- 91 T. Grassby, G. Mandalari, M. M.-L. Grundy, C. H. Edwards, C. Bisignano, D. Trombetta, A. Smeriglio, S. Chessa, S. Ray and J. Sanderson, In vitro and in vivo modeling of lipid bioaccessibility and digestion from almond muffins: The importance of the cell-wall barrier mechanism, *J. Funct. Foods*, 2017, **37**, 263–271.
- 92 G. Mandalari, N. M. Rigby, C. Bisignano, R. B. L. Curto, F. Mulholland, M. Su, M. Venkatachalam, J. M. Robotham, L. N. Willison and K. Lapsley, Effect of food matrix and processing on release of almond protein during simulated digestion, *LWT – Food Sci. Technol.*, 2014, **59**, 439–447.
- 93 S. Ballance, S. Sahlstrøm, P. Lea, N. E. Nagy, P. V. Andersen, T. Dessev, S. Hull, M. Vardakou and R. Faulks, Evaluation of gastric processing and duodenal digestion of starch in six cereal meals on the associated glycaemic response using an adult fasted dynamic gastric model, *Eur. J. Nutr.*, 2013, **52**, 799–812.
- 94 G. Mandalari, C. Bisignano, A. Filocamo, S. Chessa, M. Sarò, G. Torre, R. M. Faulks and P. Dugo, Bioaccessibility of pistachio polyphenols, xanthophylls, and tocopherols during simulated human digestion, *Nutrition*, 2013, **29**, 338–344.
- 95 A. L. Curto, I. Pitino, G. Mandalari, J. R. Dainty, R. M. Faulks and M. S. J. Wickham, Survival of probiotic lactobacilli in the upper gastrointestinal tract using an in vitro gastric model of digestion, *Food Microbiol.*, 2011, **28**, 1359–1366.
- 96 M. Kamba, Y. Seta, A. Kusai, M. Ikeda and K. Nishimura, A unique dosage form to evaluate the mechanical destructive force in the gastrointestinal tract, *Int. J. Pharm.*, 2000, **208**, 61–70.
- 97 M. J. Vassallo, M. Camilleri, C. M. Prather, R. Hanson and G. Thomforde, Measurement of axial forces during emptying from the human stomach, *Am. J. Physiol.: Gastrointest. Liver Physiol.*, 1992, **263**, G230–G239.
- 98 F. Kong, M. H. Oztop, R. P. Singh and M. J. McCarthy, Physical changes in white and brown rice during simulated gastric digestion, *J. Food Sci.*, 2011, **76**, E450–E457.
- 99 L. N. Panlasigui and L. U. Thompson, Blood glucose lowering effects of brown rice in normal and diabetic subjects, *Int. J. Food Sci. Nutr.*, 2006, **57**, 151–158.
- 100 Q. Guo, A. Ye, M. Lad, D. Dalgleish and H. Singh, Effect of gel structure on the gastric digestion of whey protein emulsion gels, *Soft Matter*, 2014, **10**, 1214–1223.
- 101 Q. Guo, A. Ye, M. Lad, M. Ferrua, D. Dalgleish and H. Singh, Disintegration kinetics of food gels during gastric digestion and its role on gastric emptying: an in vitro analysis, *Food Funct.*, 2015, **6**, 756–764.
- 102 A. Ye, J. Cui, D. Dalgleish and H. Singh, Formation of a structured clot during the gastric digestion of milk: Impact on the rate of protein hydrolysis, *Food Hydrocolloids*, 2016, **52**, 478–486.
- 103 A. Ye, J. Cui, D. Dalgleish and H. Singh, The formation and breakdown of structured clots from whole milk during gastric digestion, *Food Funct.*, 2016, **7**, 4259–4266.
- 104 A. Ye, J. Cui, D. Dalgleish and H. Singh, Effect of homogenization and heat treatment on the behavior of protein and fat globules during gastric digestion of milk, *J. Dairy Sci.*, 2017, **100**, 36–47.
- 105 G. Mandalari, M. Vardakou, R. Faulks, C. Bisignano, M. Martorana, A. Smeriglio and D. Trombetta, Food matrix effects of polyphenol bioaccessibility from almond skin during simulated human digestion, *Nutrients*, 2016, **8**, 568.
- 106 A. Lopez de Lacey, B. Giménez, E. Pérez-Santín, R. Faulks, G. Mandalari, M. López-Caballero and P. Montero, Bioaccessibility of green tea polyphenols incorporated into an edible agar film during simulated human digestion, *Food Res. Int.*, 2012, **48**, 462–469.
- 107 N. López-Barón, D. Sagnelli, A. Blennow, M. Holse, J. Gao, L. Saaby, A. Müllertz, B. Jespersen and T. Vasanthan, Hydrolysed pea proteins mitigate in vitro wheat starch digestibility, *Food Hydrocolloids*, 2018, **79**, 117–126.
- 108 G. Mandalari, Z. Merali, P. Ryden, S. Chessa, C. Bisignano, D. Barreca, E. Bellocco, G. Laganà, R. M. Faulks and K. W. Waldron, Durum wheat particle size affects starch and protein digestion in vitro, *Eur. J. Nutr.*, 2018, **57**, 319–325.
- 109 X. Wang, A. Ye, Q. Lin, J. Han and H. Singh, Gastric digestion of milk protein ingredients: Study using an in vitro dynamic model, *J. Dairy Sci.*, 2018, **101**, 6842–6852.
- 110 X. Wang, Q. Lin, A. Ye, J. Han and H. Singh, Flocculation of oil-in-water emulsions stabilised by milk protein ingredients under gastric conditions: Impact on in vitro intestinal lipid digestion, *Food Hydrocolloids*, 2019, **88**, 272–282.
- 111 A. Ye, X. Wang, Q. Lin, J. Han and H. Singh, Dynamic gastric stability and in vitro lipid digestion of whey-protein-stabilised emulsions: Effect of heat treatment, *Food Chem.*, 2020, **318**, 126463.
- 112 E. Barroso, C. Cueva, C. Peláez, M. C. Martínez-Cuesta and T. Requena, Development of human colonic microbiota in the computer-controlled dynamic SIMulator of the GastroIntestinal tract SIMGI, *LWT – Food Sci. Technol.*, 2015, **61**, 283–289.
- 113 T. Van de Wiele, P. Van den Abbeele, W. Ossieur, S. Possemiers and M. Marzorati, in *The impact of food bioactives on health*, Springer, Cham, 2015, pp. 305–317.
- 114 M. Minekus, P. Marteau and R. Havenaar, Multicompartmental dynamic computer-controlled model



- simulating the stomach and small intestine, *ATLA, Altern. Lab. Anim.*, 1995, **23**(2), 197–209.
- 115 C. VILLEMEJANE, R. WAHL, P. AYMARD, S. DENIS and C. MICHON, In vitro digestion of short-dough biscuits enriched in proteins and/or fibres, using a multi-compartmental and dynamic system (1): Viscosity measurement and prediction, *Food Chem.*, 2015, **182**, 55–63.
- 116 C. VILLEMEJANE, S. DENIS, A. MARSSÉ-BAGLIERI, M. ALRIC, P. AYMARD and C. MICHON, In vitro digestion of short-dough biscuits enriched in proteins and/or fibres using a multi-compartmental and dynamic system (2): Protein and starch hydrolyses, *Food Chem.*, 2016, **190**, 164–172.
- 117 F. M. ALHASAWI, D. FONDACO, K. BEN-ELAZAR, S. BEN-ELAZAR, Y. Y. FAN, M. G. CORRADINI, R. D. LUDESCHER, D. BOLSTER, G. CARDER and Y. CHU, In vitro measurements of luminal viscosity and glucose/maltose bioaccessibility for oat bran, instant oats, and steel cut oats, *Food Hydrocolloids*, 2017, **70**, 293–303.
- 118 C. NIMALARATNE, P. SAVARD, S. F. GAUTHIER, A. SCHIEBER and J. WU, Bioaccessibility and digestive stability of carotenoids in cooked eggs studied using a dynamic in vitro gastrointestinal model, *J. Agric. Food Chem.*, 2015, **63**, 2956–2962.
- 119 S. BLANQUET-DIOT, M. SOUFI, M. RAMBEAU, E. ROCK and M. ALRIC, Digestive stability of xanthophylls exceeds that of carotenes as studied in a dynamic in vitro gastrointestinal system, *J. Nutr.*, 2009, **139**, 876–883.
- 120 E. DEAT, S. BLANQUET-DIOT, J.-F. JARRIGE, S. DENIS, E. BEYSSAC and M. ALRIC, Combining the dynamic TNO-gastrointestinal tract system with a Caco-2 cell culture model: Application to the assessment of lycopene and α -tocopherol bioavailability from a whole food, *J. Agric. Food Chem.*, 2009, **57**, 11314–11320.
- 121 M. VERWEI, M. MINEKUS, E. ZEIJDNER, R. SCHILDERINK and R. HAVENAAR, Evaluation of two dynamic in vitro models simulating fasted and fed state conditions in the upper gastrointestinal tract (TIM-1 and tiny-TIM) for investigating the bioaccessibility of pharmaceutical compounds from oral dosage forms, *Int. J. Pharm.*, 2016, **498**, 178–186.
- 122 A. OOSTERVELD, M. MINEKUS, E. BOMHOF, F. D. ZOET and G. A. VAN AKEN, Effects of inhomogeneity on triglyceride digestion of emulsions using an in vitro digestion model (Tiny TIM), *Food Funct.*, 2016, **7**, 2979–2995.
- 123 A. HELBIG, E. SILLETTI, G. A. VAN AKEN, A. OOSTERVELD, M. MINEKUS, R. J. HAMER and H. GRUPPEN, Lipid Digestion of Protein Stabilized Emulsions Investigated in a Dynamic In Vitro Gastro-Intestinal Model System, *Food Dig.*, 2013, **4**, 58–68.
- 124 O. MÉNARD, T. CATTENOZ, H. GUILLEMIN, I. SOUCHON, A. DEGLAIRE, D. DUPONT and D. PICQUE, Validation of a new in vitro dynamic system to simulate infant digestion, *Food Chem.*, 2014, **145**, 1039–1045.
- 125 S. C. DE OLIVEIRA, A. DEGLAIRE, O. MÉNARD, A. BELLANGER, F. ROUSSEAU, G. HENRY, E. DIRSON, F. CARRIÈRE, D. DUPONT and C. BOURLIEU, Holder pasteurization impacts the proteolysis, lipolysis and disintegration of human milk under in vitro dynamic term newborn digestion, *Food Res. Int.*, 2016, **88**(Part B), 263–275.
- 126 L. SÁNCHEZ-RIVERA, O. MÉNARD, I. RECIO and D. DUPONT, Peptide mapping during dynamic gastric digestion of heated and unheated skimmed milk powder, *Food Res. Int.*, 2015, **77**, 132–139.
- 127 F. BARBÉ, O. MÉNARD, Y. LE GOUAR, C. BUFFIÈRE, M.-H. FAMELART, B. LAROCHE, S. LE FEUNTEUN, D. DUPONT and D. RÉMOND, The heat treatment and the gelation are strong determinants of the kinetics of milk proteins digestion and of the peripheral availability of amino acids, *Food Chem.*, 2013, **136**, 1203–1212.
- 128 M. N. CORSTENS, C. C. BERTON-CARABIN, K. SCHROËN, M. VIAU and A. MEYNIER, Emulsion encapsulation in calcium-alginate beads delays lipolysis during dynamic in vitro digestion, *J. Funct. Foods*, 2018, **46**, 394–402.
- 129 D. FREITAS and S. LE FEUNTEUN, Oro-gastro-intestinal digestion of starch in white bread, wheat-based and gluten-free pasta: unveiling the contribution of human salivary α -amylase, *Food Chem.*, 2019, **274**, 566–573.
- 130 L. BARROS, C. RETAMAL, H. TORRES, R. N. ZUNIGA and E. TRONCOSO, Development of an in vitro mechanical gastric system (IMGS) with realistic peristalsis to assess lipid digestibility, *Food Res. Int.*, 2016, **90**, 216–225.
- 131 J. J. WANG, P. WU, M. H. LIU, Z. K. LIAO, Y. WANG, Z. Z. DONG and X. D. CHEN, An advanced near real dynamic in vitro human stomach system to study gastric digestion and emptying of beef stew and cooked rice, *Food Funct.*, 2019, **10**, 2914–2925.
- 132 Y. W. LI, L. FORTNER and F. B. KONG, Development of a Gastric Simulation Model (GSM) incorporating gastric geometry and peristalsis for food digestion study, *Food Res. Int.*, 2019, **125**, 108598.
- 133 M. L. ALMINGER, C. EKLUND-JONSSON, S. KIDMAN and M. LANGTON, Starch microstructure and starch hydrolysis in barley and oat tempe during in vitro digestion, *Food Dig.*, 2012, **3**, 53–62.
- 134 D. P. JOHANSSON, J. L. V. GUTIÉRREZ, R. LANDBERG, M. ALMINGER and M. LANGTON, Impact of food processing on rye product properties and their in vitro digestion, *Eur. J. Nutr.*, 2018, **57**, 1651–1666.
- 135 J. KARTHIKEYAN, D. SALVI, M. G. CORRADINI, R. D. LUDESCHER and M. V. KARWE, Effect of bolus viscosity on carbohydrate digestion and glucose absorption processes: An in vitro study, *Phys. Fluids*, 2019, **31**, 111905.
- 136 F. M. ALHASAWI, D. FONDACO, M. G. CORRADINI, R. D. LUDESCHER, D. BOLSTER, Y. CHU, Y. CHUNG, J. JOHNSON and M. A. ROGERS, Gastric viscosity and sugar bioaccessibility of instant and steel cut oat/milk protein blends, *Food Hydrocolloids*, 2018, **82**, 424–433.
- 137 A. SPERANZA, M. CORRADINI, T. HARTMAN, D. RIBNICKY, A. OREN and M. ROGERS, Influence of emulsifier structure on lipid bioaccessibility in oil–water nanoemulsions, *J. Agric. Food Chem.*, 2013, **61**, 6505–6515.
- 138 B. FRAMROZE, P. SAVARD, D. GAGNON, V. RICHARD and S. F. GAUTHIER, Comparison of nitrogen bioaccessibility



- from salmon and whey protein hydrolysates using a human gastrointestinal model (TIM-1), *Funct. Foods Health Dis.*, 2014, **4**, 222–231.
- 139 N. M. Anson, R. Havenaar, A. Bast and G. R. Haenen, Antioxidant and anti-inflammatory capacity of bioaccessible compounds from wheat fractions after gastrointestinal digestion, *J. Cereal Sci.*, 2010, **51**, 110–114.
- 140 M. Larsson, M. Minekus and R. Havenaar, Estimation of the bioavailability of iron and phosphorus in cereals using a dynamic in vitro gastrointestinal model, *J. Sci. Food Agric.*, 1997, **74**, 99–106.
- 141 C. A. Van Loo-Bouwman, T. H. Naber, M. Minekus, R. B. Van Breemen, P. J. Hulshof and G. Schaafsma, Food matrix effects on bioaccessibility of β -carotene can be measured in an in vitro gastrointestinal model, *J. Agric. Food Chem.*, 2014, **62**, 950–955.
- 142 M. A. Lila, D. M. Ribnicky, L. E. Rojo, P. Rojas-Silva, A. Oren, R. Havenaar, E. M. Janle, I. Raskin, G. G. Yousef and M. H. Grace, Complementary approaches to gauge the bioavailability and distribution of ingested berry polyphenolics, *J. Agric. Food Chem.*, 2012, **60**, 5763–5771.
- 143 M. Verwei, K. Arkbåge, R. Havenaar, H. van den Berg, C. Witthöft and G. Schaafsma, Folic acid and 5-methyltetrahydrofolate in fortified milk are bioaccessible as determined in a dynamic in vitro gastrointestinal model, *J. Nutr.*, 2003, **133**, 2377–2383.
- 144 O. Ménard, M.-H. Famelart, A. Deglaire, Y. Le Gouar, S. Guérin, C.-H. Malbert and D. Dupont, Gastric Emptying and Dynamic In Vitro Digestion of Drinkable Yogurts: Effect of Viscosity and Composition, *Nutrients*, 2018, **10**, 1308.
- 145 D. Freitas and S. Le Feunteun, Inhibitory effect of black tea, lemon juice, and other beverages on salivary and pancreatic amylases: What impact on bread starch digestion? A dynamic in vitro study, *Food Chem.*, 2019, **297**, 124885.
- 146 A. Deglaire, S. C. De Oliveira, J. Jardin, V. Briard-Bion, M. Emily, O. Ménard, C. Bourlieu and D. Dupont, Impact of human milk pasteurization on the kinetics of peptide release during in vitro dynamic term newborn digestion, *Electrophoresis*, 2016, **37**, 1839–1850.
- 147 R. Holmes and R. W. Lobley, Intestinal brush border revisited, *Gut*, 1989, **30**, 1667–1678.
- 148 R. E. McConnell, A. E. Benesh, S. Mao, D. L. Tabb and M. J. Tyska, Proteomic analysis of the enterocyte brush border, *Am. J. Physiol.: Gastrointest. Liver Physiol.*, 2011, **300**, G914–G926.
- 149 J. F. Woodley, Enzymatic barriers for GI peptide and protein delivery, *Crit. Rev. Ther. Drug Carrier Syst.*, 1994, **11**, 61–95.
- 150 G. Picariello, P. Ferranti and F. Addeo, Use of brush border membrane vesicles to simulate the human intestinal digestion, *Food Res. Int.*, 2016, **88**, 327–335.
- 151 F. Waldeck, in *Human Physiology*, ed. R. F. Schmidt and G. Thews, Springer-Verlag, Berlin-Heidelberg-New York, 1983, ch. 26.
- 152 L. Shan, O. Molberg, I. Parrot, F. Hausch, F. Filiz, G. M. Gray, L. M. Sollid and C. Khosla, Structural basis for gluten intolerance in celiac sprue, *Science*, 2002, **297**, 2275–2279.
- 153 G. Picariello, B. Miralles, G. Mamone, L. Sanchez-Rivera, I. Recio, F. Addeo and P. Ferranti, Role of intestinal brush border peptidases in the simulated digestion of milk proteins, *Mol. Nutr. Food Res.*, 2015, **59**, 948–956.
- 154 J. K. Patterson, X. G. Lei and D. D. Miller, The pig as an experimental model for elucidating the mechanisms governing dietary influence on mineral absorption, *Exp. Biol. Med.*, 2008, **233**, 651–664.
- 155 N. Mach, M. Berri, D. Esquerre, C. Chevalyere, G. Lemonnier, Y. Billon, P. Lepage, I. P. Oswald, J. Dore, C. Rogel-Gaillard and J. Estelle, Extensive expression differences along porcine small intestine evidenced by transcriptome sequencing, *PLoS One*, 2014, **9**, e88515.
- 156 S. P. Shirazi-Beechey, A. G. Davies, K. Tebbutt, J. Dyer, A. Ellis, C. J. Taylor, P. Fairclough and R. B. Beechey, Preparation and properties of brush-border membrane vesicles from human small intestine, *Gastroenterology*, 1990, **98**, 676–685.
- 157 M. Claude, R. Lupi, G. Picariello, M. Drouet, C. Larre, S. Denery-Papini and C. Brossard, Digestion differently affects the ability of native and thermally aggregated ovalbumin to trigger basophil activation, *Food Res. Int.*, 2019, **118**, 108–114.
- 158 L. Di Stasio, O. Tranquet, G. Picariello, P. Ferranti, M. Morisset, S. Denery-Papini and G. Mamone, Comparative analysis of eliciting capacity of raw and roasted peanuts: the role of gastrointestinal digestion, *Food Res. Int.*, 2020, **127**, 108758.
- 159 C. Gianfrani, A. Camarca, G. Mazzarella, L. Di Stasio, N. Giardullo, P. Ferranti, G. Picariello, V. R. Aufiero, S. Picascia, R. Troncone, N. Pogna, S. Auricchio and G. Mamone, Extensive in vitro gastrointestinal digestion markedly reduces the immune-toxicity of Triticum monococcum wheat: implication for celiac disease, *Mol. Nutr. Food Res.*, 2015, **59**, 1844–1854.
- 160 J. L. Piper, G. M. Gray and C. Khosla, Effect of prolyl endopeptidase on digestive-resistant gliadin peptides in vivo, *J. Pharmacol. Exp. Ther.*, 2004, **311**, 213–219.
- 161 A. H.-M. Lin, B.-H. Lee and W.-J. Chang, Small intestine mucosal α -glucosidase: A missing feature of in vitro starch digestibility, *Food Hydrocolloids*, 2016, **53**, 163–171.
- 162 O. Hernandez-Hernandez, A. Olano, R. A. Rastall and F. J. Moreno, In vitro Digestibility of Dietary Carbohydrates: Toward a Standardized Methodology Beyond Amyolytic and Microbial Enzymes, *Front. Nutr.*, 2019, **6**, 61.
- 163 S. Howell, A. J. Kenny and A. J. Turner, A survey of membrane peptidases in two human colonic cell lines, Caco-2 and HT-29, *Biochem. J.*, 1992, **284**(Pt 2), 595–601.
- 164 G. Picariello, G. Iacomino, G. Mamone, P. Ferranti, O. Fierro, C. Gianfrani, A. Di Luccia and F. Addeo, Transport across Caco-2 monolayers of peptides arising



- from in vitro digestion of bovine milk proteins, *Food Chem.*, 2013, **139**, 203–212.
- 165 S. Howell, I. A. Brewis, N. M. Hooper, A. J. Kenny and A. J. Turner, Mosaic expression of membrane peptidases by confluent cultures of Caco-2 cells, *FEBS Lett.*, 1993, **317**, 109–112.
- 166 K. Gunathilake, K. Ranaweera and H. P. V. Rupasinghe, Change of phenolics, carotenoids, and antioxidant capacity following simulated gastrointestinal digestion and dialysis of selected edible green leaves, *Food Chem.*, 2018, **245**, 371–379.
- 167 S. Blanquet, E. Zeijdner, E. Beyssac, J. P. Meunier, S. Denis, R. Havenaar and M. Alric, A dynamic artificial gastrointestinal system for studying the behavior of orally administered drug dosage forms under various physiological conditions, *Pharm. Res.*, 2004, **21**, 585–591.
- 168 I. J. Hidalgo, T. J. Raub and R. T. Borchardt, Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability, *Gastroenterology*, 1989, **96**, 736–749.
- 169 J. M. Gamboa and K. W. Leong, In vitro and in vivo models for the study of oral delivery of nanoparticles, *Adv. Drug Delivery Rev.*, 2013, **65**, 800–810.
- 170 M. Pinto, S. Robineleon and M. D. Appay, Enterocyte-like differentiation and polarization of the human colon carcinoma cell line Caco-2 in culture, *Biol. Cell*, 1983, **47**, 323–330.
- 171 K. Verhoeckx, P. Cotter, I. Lopez-Exposito, C. Kleiveland, T. Lea, A. Mackie, T. Requena, D. Swiatecka and H. Wichers, *The Impact of Food Bioactives on Health: in vitro and ex vivo models*, Springer International Publishing, Cham (CH), 2015.
- 172 C. Vors, P. Capolino, C. Guerin, E. Meugnier, S. Pesenti, M. A. Chauvin, J. Monteil, N. Peretti, M. Cansell, F. Carriere and M. C. Michalski, Coupling in vitro gastrointestinal lipolysis and Caco-2 cell cultures for testing the absorption of different food emulsions, *Food Funct.*, 2012, **3**, 537–546.
- 173 V. D. Felice, D. M. O’Gorman, N. M. O’Brien and N. P. Hyland, Bioaccessibility and Bioavailability of a Marine-Derived Multimineral, Aquamin-Magnesium, *Nutrients*, 2018, **10**, 912.
- 174 H. J. Kim, D. Huh, G. Hamilton and D. E. Ingber, Human gut-on-a-chip inhabited by microbial flora that experiences intestinal peristalsis-like motions and flow, *Lab Chip*, 2012, **12**, 2165–2174.
- 175 N. Gunness, J. Michiels, S. De Smet, L. Vanhaecke, O. Kravchuk and M. Gidley, Blood lipids – soluble dietary fibres: Study of bile salts diffusion across intestinal mucosa using the Ussing chamber system, *J. Nutr. Intermed. Metab.*, 2016, **4**, 35.
- 176 D. A. Norris and P. J. Sinko, Effect of size, surface charge, and hydrophobicity on the translocation of polystyrene microspheres through gastrointestinal mucin, *J. Appl. Polym. Sci.*, 1997, **63**, 1481–1492.
- 177 K. M. Hillgren, A. Kato and R. T. Borchardt, In vitro systems for studying intestinal drug absorption, *Med. Res. Rev.*, 1995, **15**, 83–109.
- 178 A. Trapani, A. Lopodota, M. Franco, N. Cioffi, E. Ieva, M. Garcia-Fuentes and M. J. Alonso, A comparative study of chitosan and chitosan/cyclodextrin nanoparticles as potential carriers for the oral delivery of small peptides, *Eur. J. Pharm. Biopharm.*, 2010, **75**, 26–32.
- 179 S. M. Kalman and H. H. Ussing, Active sodium uptake by the toad and its response to the antidiuretic hormone, *J. Gen. Physiol.*, 1955, **38**, 361–370.
- 180 P. B. Persson, Did you know? The Ussing chamber origin, *Acta Physiol.*, 2016, **218**, 67–67.
- 181 L. L. Clarke, A guide to Ussing chamber studies of mouse intestine, *Am. J. Physiol.: Gastrointest. Liver Physiol.*, 2009, **296**, G1151–G1166.
- 182 P. Lundquist and P. Artursson, Oral absorption of peptides and nanoparticles across the human intestine: Opportunities, limitations and studies in human tissues, *Adv. Drug Delivery Rev.*, 2016, **106**, 256–276.
- 183 A. M. Rowan, P. J. Moughan, M. N. Wilson, K. Maher and C. Tasman-Jones, Comparison of the ileal and faecal digestibility of dietary amino acids in adult humans and evaluation of the pig as a model animal for digestion studies in man, *Br. J. Nutr.*, 1994, **71**, 29–42.
- 184 J. García, D. Méndez, M. Álvarez, B. Sanmartin, R. Vázquez, L. Regueiro and M. Atanassova, Design of novel functional food products enriched with bioactive extracts from holothurians for meeting the nutritional needs of the elderly, *LWT – Food Sci. Technol.*, 2019, **109**, 55–62.
- 185 A. Mackie, S. Gourey, N. Rigby, J. Moffat, I. Capron and B. Bajka, The fate of cellulose nanocrystal stabilised emulsions after simulated gastrointestinal digestion and exposure to intestinal mucosa, *Nanoscale*, 2019, **11**, 2991–2998.
- 186 M. Foltz, A. Cerstiaens, A. van Meensel, R. Mols, P. C. van der Pijl, G. S. Duchateau and P. Augustijns, The angiotensin converting enzyme inhibitory tripeptides Ile-Pro-Pro and Val-Pro-Pro show increasing permeabilities with increasing physiological relevance of absorption models, *Peptides*, 2008, **29**, 1312–1320.
- 187 V. Rozehnal, D. Nakai, U. Hoepner, T. Fischer, E. Kamiyama, M. Takahashi, S. Yasuda and J. Mueller, Human small intestinal and colonic tissue mounted in the Ussing chamber as a tool for characterizing the intestinal absorption of drugs, *Eur. J. Pharm. Sci.*, 2012, **46**, 367–373.
- 188 A. Sjoberg, M. Lutz, C. Tannergren, C. Wingolf, A. Borde and A. L. Ungell, Comprehensive study on regional human intestinal permeability and prediction of fraction absorbed of drugs using the Ussing chamber technique, *Eur. J. Pharm. Sci.*, 2013, **48**, 166–180.
- 189 S. M. Harrison, G. Eyres, P. W. Cleary, M. D. Sinnott, C. Delahunty and L. Lundin, Computational Modeling of Food Oral Breakdown Using Smoothed Particle Hydrodynamics, *J. Texture Stud.*, 2014, **45**, 97–109.



- 190 C. A. M. Fois, T. Y. L. Le, A. Schindeler, S. Naficy, D. D. McClure, M. N. Read, P. Valtchev, A. Khademhosseini and F. Dehghani, Models of the Gut for Analyzing the Impact of Food and Drugs, *Adv. Healthcare Mater.*, 2019, **8**, 1900968.
- 191 N. Parrott, C. Stillhart, M. Lindenberg, B. Wagner, K. Kowalski, E. Guerini, N. Djebli and G. Meneses-Lorente, Physiologically Based Absorption Modelling to Explore the Impact of Food and Gastric pH Changes on the Pharmacokinetics of Entrectinib, *AAPS J.*, 2020, **22**, 13.
- 192 K. C. Drechsler and M. J. Ferrua, Modelling the breakdown mechanics of solid foods during gastric digestion, *Food Res. Int.*, 2016, **88**, 181–190.
- 193 S. M. Harrison, P. W. Cleary and M. D. Sinnott, Investigating mixing and emptying for aqueous liquid content from the stomach using a coupled biomechanical-SPH model, *Food Funct.*, 2018, **9**, 3202–3219.
- 194 T. E. Moxon, O. Gouseti and S. Bakalis, In silico modelling of mass transfer & absorption in the human gut, *J. Food Eng.*, 2016, **176**, 110–120.
- 195 R. G. Lentle and C. de Loubens, A review of mixing and propulsion of chyme in the small intestine: fresh insights from new methods, *J. Comp. Physiol., B*, 2015, **185**, 369–387.
- 196 M. D. Sinnott, P. W. Cleary, J. W. Arkwright and P. G. Dinning, Modeling Colonic Motility: How Does Descending Inhibition Influence the Transport of Fluid?, *Gastroenterology*, 2011, **140**, S865–S866.
- 197 S. Marze, Refining in silico simulation to study digestion parameters affecting the bioaccessibility of lipophilic nutrients and micronutrients, *Food Funct.*, 2015, **6**, 115–124.
- 198 T. Sayd, C. Dufour, C. Chambon, C. Buffiere, D. Remond and V. Sante-Lhoutellier, Combined in vivo and in silico approaches for predicting the release of bioactive peptides from meat digestion, *Food Chem.*, 2018, **249**, 111–118.
- 199 S. Bellmann, S. Krishnan, A. de Graaf, R. A. de Ligt, W. J. Pasman, M. Minekus and R. Havenaar, Appetite ratings of foods are predictable with an in vitro advanced gastrointestinal model in combination with an in silico artificial neural network, *Food Res. Int.*, 2019, **122**, 77–86.
- 200 FAO, *Dietary protein quality evaluation in human nutrition: report of an FAO expert consultation*, 2013, vol. 92.
- 201 M. Dangin, C. Guillet, C. Garcia-Rodenas, P. Gachon, C. Bouteloup-Demange, K. Reiffers-Magnani, J. Fauquant, O. Ballèvre and B. Beaufrère, The rate of protein digestion affects protein gain differently during aging in humans, *J. Physiol.*, 2003, **549**, 635–644.
- 202 L. Egger, P. Schlegel, C. Baumann, H. Stoffers, D. Guggisberg, C. Brugger, D. Durr, P. Stoll, G. Vergeres and R. Portmann, Physiological comparability of the harmonized INFOGEST in vitro digestion method to in vivo pig digestion, *Food Res. Int.*, 2017, **102**, 567–574.
- 203 M. Yvon, S. Beucher, P. Scanff, S. Thirouin and J. P. Pelissier, In vitro simulation of gastric digestion of milk proteins: comparison between in vitro and in vivo data, *J. Agric. Food Chem.*, 1992, **40**, 239–244.
- 204 A. Maathuis, R. Havenaar, T. He and S. Bellmann, Protein digestion and quality of goat and cow milk infant formula and human milk under simulated infant conditions, *J. Pediatr. Gastroenterol. Nutr.*, 2017, **65**, 661.
- 205 M. Golding, T. J. Wooster, L. Day, M. Xu, L. Lundin, J. Keogh and P. Clifton, Impact of gastric structuring on the lipolysis of emulsified lipids, *Soft Matter*, 2011, **7**, 3513–3523.
- 206 A. Steingoetter, T. Radovic, S. Buetikofer, J. Curcic, D. Menne, M. Fried, W. Schwizer and T. J. Wooster, Imaging gastric structuring of lipid emulsions and its effect on gastrointestinal function: a randomized trial in healthy subjects, *Am. J. Clin. Nutr.*, 2015, **101**, 714–724.
- 207 A. R. Mackie, H. Rafiee, P. Malcolm, L. Salt and G. van Aken, Specific food structures suppress appetite through reduced gastric emptying rate, *Am. J. Physiol.: Gastrointest. Liver Physiol.*, 2013, **304**, G1038–G1043.
- 208 D. Jenkins, T. Wolever, R. H. Taylor, H. Barker, H. Fielden, J. M. Baldwin, A. C. Bowling, H. C. Newman, A. L. Jenkins and D. V. Goff, Glycemic index of foods: a physiological basis for carbohydrate exchange, *Am. J. Clin. Nutr.*, 1981, **34**, 362–366.
- 209 A. W. Barclay, P. Petocz, J. McMillan-Price, V. M. Flood, T. Prvan, P. Mitchell and J. C. Brand-Miller, Glycemic index, glycemic load, and chronic disease risk—a meta-analysis of observational studies, *Am. J. Clin. Nutr.*, 2008, **87**, 627–637.
- 210 H. N. Englyst, S. Kingman and J. Cummings, Classification and measurement of nutritionally important starch fractions, *Eur. J. Clin. Nutr.*, 1992, **46**, S33–S50.
- 211 K. N. Englyst, H. N. Englyst, G. J. Hudson, T. J. Cole and J. H. Cummings, Rapidly available glucose in foods: an in vitro measurement that reflects the glycemic response, *Am. J. Clin. Nutr.*, 1999, **69**, 448–454.
- 212 I. Goñi, A. Garcia-Alonso and F. Saura-Calixto, A starch hydrolysis procedure to estimate glycemic index, *Nutr. Res.*, 1997, **17**, 427–437.
- 213 J. W. Woolnough, J. A. Monro, C. S. Brennan and A. R. Bird, Simulating human carbohydrate digestion in vitro: a review of methods and the need for standardisation, *Int. J. Food Sci. Technol.*, 2008, **43**, 2245–2256.
- 214 K. A. Germaine, S. Samman, C. G. Fryirs, P. J. Griffiths, S. K. Johnson and K. J. Quail, Comparison of in vitro starch digestibility methods for predicting the glycaemic index of grain foods, *J. Sci. Food Agric.*, 2008, **88**, 652–658.
- 215 M. Alminger and C. Eklund-Jonsson, Whole-grain cereal products based on a high-fibre barley or oat genotype lower post-prandial glucose and insulin responses in healthy humans, *Eur. J. Nutr.*, 2008, **47**, 294.
- 216 S. Bellmann, M. Minekus, E. Zeijdner, M. Verwei, P. Sanders, W. Basten and R. Havenaar, *TIM-carbo: a rapid, cost-efficient and reliable in vitro method for glycaemic response after carbohydrate ingestion*, *Dietary fibre: new fron-*



- tiers for food and health*, Wageningen Academic Publishers, Wageningen, 2010, pp. 467–473.
- 217 D. Gentilcore, R. Chaikomin, K. L. Jones, A. Russo, C. Feinle-Bisset, J. M. Wishart, C. K. Rayner and M. Horowitz, Effects of fat on gastric emptying of and the glycemic, insulin, and incretin responses to a carbohydrate meal in type 2 diabetes, *J. Clin. Endocrinol. Metab.*, 2006, **91**, 2062–2067.
- 218 E. Reboul, M. Richelle, E. Perrot, C. Desmoulins-Malezet, V. Pirisi and P. Borel, Bioaccessibility of carotenoids and vitamin E from their main dietary sources, *J. Agric. Food Chem.*, 2006, **54**, 8749–8755.
- 219 V. Tyssandier, E. Reboul, J.-F. Dumas, C. Bouteloup-Demange, M. Armand, J. Marcand, M. Sallas and P. Borel, Processing of vegetable-borne carotenoids in the human stomach and duodenum, *Am. J. Physiol.: Gastrointest. Liver Physiol.*, 2003, **284**, G913–G923.
- 220 C. Vetrani, A. A. Rivellese, G. Annuzzi, M. Adiels, J. Borén, I. Mattila, M. Orešič and A.-M. Aura, Metabolic transformations of dietary polyphenols: comparison between in vitro colonic and hepatic models and in vivo urinary metabolites, *J. Nutr. Biochem.*, 2016, **33**, 111–118.
- 221 M. Verwei, A. P. Freidig, R. Havenaar and J. P. Groten, Predicted serum folate concentrations based on in vitro studies and kinetic modeling are consistent with measured folate concentrations in humans, *J. Nutr.*, 2006, **136**, 3074–3078.
- 222 P. Etcheverry, M. A. Grusak and L. E. Fleige, Application of in vitro bioaccessibility and bioavailability methods for calcium, carotenoids, folate, iron, magnesium, polyphenols, zinc, and vitamins B6, B12, D, and E, *Front. Physiol.*, 2012, **3**, 317.
- 223 T. J. Wooster, L. Day, M. Xu, M. Golding, S. Oiseth, J. Keogh and P. Clifton, Impact of different biopolymer networks on the digestion of gastric structured emulsions, *Food Hydrocolloids*, 2014, **36**, 102–114.
- 224 D. Jenkins, H. Ghafari, T. Wolever, R. Taylor, A. Jenkins, H. Barker, H. Fielden and A. Bowling, Relationship between rate of digestion of foods and post-prandial glycaemia, *Diabetologia*, 1982, **22**, 450–455.
- 225 A. Ferrer-Mairal, C. Penalva-Lapuente, I. Iglesia, L. Urtasun, P. De Miguel-Etayo, S. Remón, E. Cortés and L. Moreno, In vitro and in vivo assessment of the glycemic index of bakery products: influence of the reformulation of ingredients, *Eur. J. Nutr.*, 2012, **51**, 947–954.
- 226 C. H. Edwards, M. M. Grundy, T. Grassby, D. Vasilopoulou, G. S. Frost, P. J. Butterworth, S. E. Berry, J. Sanderson and P. R. Ellis, Manipulation of starch bioaccessibility in wheat endosperm to regulate starch digestion, postprandial glycaemia, insulinemia, and gut hormone responses: a randomized controlled trial in healthy ileostomy participants, *Am. J. Clin. Nutr.*, 2015, **102**, 791–800.
- 227 T. Walter, F. Pizarro and M. Olivares, Iron bioavailability in corn-masa tortillas is improved by the addition of disodium EDTA, *J. Nutr.*, 2003, **133**, 3158–3161.
- 228 R. J. de Jong, M. Verwei, C. E. West, T. van Vliet, E. Siebelink, H. van den Berg and J. J. Castenmiller, Bioavailability of folic acid from fortified pasteurised and UHT-treated milk in humans, *Eur. J. Clin. Nutr.*, 2005, **59**, 906–913.

